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During development of the peripheral nervous system, sensory axons 
extend to the periphery in excess where they compete for limiting target-derived 
neurotrophic support. Local neurotrophin insufficiency triggers axon 
degeneration, resulting in the pruning of over half of all sensory axons during 
development. Although axon degeneration facilitates the essential sculpting of 
the developing nervous system, its improper activation may underlie several 
neurodegenerative disorders. This process can be modeled in vitro by culturing 
sensory neurons from mouse dorsal root ganglia in the presence of nerve growth 
factor either as explant cultures or in compartmented chambers that allow 
independent manipulation of cell bodies and axons. The mitochondrial apoptotic 
pathway and the effector caspases, Caspase-3 and Caspase-6, mediate axon 
degeneration in both this in vitro model system and in vivo, clearly indicating a 
role for classical apoptotic machinery in axon degeneration. However, the full 
mechanism executing this process has yet to be determined. 
Previous studies proposed a model whereby the signaling mechanisms 
that driving axon degeneration in response to local deprivation resides 
completely within the axon itself. This view has been challenged by results 
showing that transcriptional inhibition prevents caspase activation in axons, as 
does physically separating the axon from its cell body. We used the in vitro 
culture system described above to address this controversy and conclusively 
show that, although the apoptotic machinery is present in axons, the cell body is 
required for gating axonal caspase activation and axon degeneration in response 
to trophic factor withdrawal. 
Use of selective pharmacological inhibitors and knockdown of candidate 
genes identifies a pathway whereby local trophic deprivation results in loss of Akt 
signaling and activation of DLK signaling, leading to activation of the JNK/c-jun 
signaling and a Foxo3a dependent transcriptional program. The cell body acts as 
a convergence point for these two pathways resulting in upregulation of the pro-
apoptotic protein Puma, itself identified through a genetic knockout screen. We 
further show that although Puma is unexpectedly confined to the cell body, rising 
levels of somatic Puma in response to trophic deprivation overcome inhibition by 
pro-survival Bcl-xL and Bcl-w to initiate an anterograde, JNK-dependent, pro-
degenerative program. Taken together, our results identify the cell body as a key 
arbiter of large-scale axon removal. 
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Chapter 1: Introduction and overview of the field 
 
Rationale for the current study 
Axon degeneration is a crucial component of normal development and 
plasticity, but aberrant degeneration is also a hallmark of neurodegenerative 
diseases, such as Alzheimer’s and Amyotrophic Lateral Sclerosis (ALS), and 
direct injury (Luo and O’Leary, 2005; Neukomm and Freeman, 2014; Pease and 
Segal, 2014; Saxena and Caroni, 2007). Several triggers initiate this process, 
which, once started, leads to swelling or blebbing of the axonal process followed 
by fragmentation and engulfment by glia or macrophages (Saxena and Caroni, 
2007). Despite garnering considerable research interest, understanding of 
mechanisms leading to degeneration remains incomplete. Elucidating key 
components of this process will yield key insights into the process of 
developmental pruning and plasticity, as well as shedding light on mechanisms of 
neurodegenerative disease progression and possible targets for therapeutic 
intervention.  
While exploring the process of axon degeneration, it is crucial to 
understand the different contexts during which it occurs. These contexts can be 
broadly divided into axon degeneration that occurs (1) during development, (2) 
following injury, or (3) during neurodegenerative disease. The full complement of 
factors operating in each context has yet to be discovered and, perhaps even 
more vital, how these factors interact and where in the cell they operate are 
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critical unanswered questions. These questions are the primary driving force 
behind the work detailed in this thesis. 
 
Axon degeneration during development  
During development, axon pruning eliminates excess and misconnected axonal 
projections and this process often occurs in the absence of neuronal cell body 
death (Luo and O’Leary, 2005; Saxena and Caroni, 2007). This phenomenon is 
observed across multiple systems from Drosophila to humans, usually occurring 
during metamorphosis in Drosophila and during postnatal development in 
vertebrates (Cowan et al., 1984; Luo and O’Leary, 2005; Schuldiner and Yaron, 
2014). In fact, it is estimated that humans prune half of all neural connections by 
the age of two and that a similar percentage of neurons are culled during mouse 
development (Cowan et al., 1984; Thompson and Nelson, 2001).  This pruning 
back of exuberant connections is vital and allows for proper axonal connectivity 
between neurons and their ultimate targets (Luo and O’Leary, 2005; Saxena and 
Caroni, 2007; Vanderhaeghen and Cheng, 2010). 
Pruning occurs through three primary mechanisms: axosome shedding, 
axon retraction, and axon degeneration (Figure 1.1). Which mechanism is 
operating in a given context is largely determined by the length of the process 
that needs to be eliminated; with shorter processes being subject to retraction or 
axosome shedding and longer processes being removed through degeneration 
(Luo and O’Leary, 2005; Neukomm and Freeman, 2014). 
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Figure 1.1 Illustration of modes of axon pruning that occur during 
development and injury. (A) A single neuron with two axonal branches is 
depicted. Axonal branch highlighted with box will be used to illustrate modes of 
pruning in panels B-D (B) Axon retraction involves withdrawal of the distal tip of 
the axon in absence of fragmentation (C) Axosome shedding involves withdrawal 
of the distal tip in a process that leaves behind membrane bound vesicles 
containing intact organelles that are later engulfed and degraded by surrounding 
cells (D) Axon degeneration, typically occurring in longer axonal processes, 
results in fragmentation and clearance of a distal portion of the axon (E) 
Wallerian degeneration occurs as a result of injury or chemical insult resulting in 
degeneration of the portion of the axon distal to the point of injury. (Figure 
reprinted with permission (Neukomm and Freeman, 2014)). 
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Axosome shedding is defined morphologically by the regression of the 
distal axon tip in a process that leaves behind membrane bound organelles, 
termed axosomes, that are later engulfed and degraded by neighboring Schwann 
cells in a lysosomal process (Bishop et al., 2004; Neukomm and Freeman, 2014; 
Song et al., 2008) (Figure 1.1C). The hallmark example of axosome shedding is 
refinement of axonal connections at the vertebrate neuromuscular junction 
(NMJ). Early in post-natal development, each NMJ is innervated by multiple 
motoneuron axons. These axonal arbors compete in an activity dependent 
manner; those that have stronger and more synchronous electrical activity are 
maintained, while the others retract, resulting in an NMJ innervated by a single 
axonal arbor from a single motoneuron (Lichtman and Colman, 2000; Luo and 
O’Leary, 2005). In this way approximately 90% of original NMJ synapses are 
eliminated without motoneuron death (Riley, 1981; Sanes and Lichtman, 1999; 
Tapia et al., 2012). Intriguingly, a similar process operates in the growth and 
retraction of axonal arbors in the Drosophila NMJ, indicating that this pruning 
mechanism is evolutionarily conserved (Fuentes-Medel et al., 2009; Liu et al., 
2010; Neukomm and Freeman, 2014).  
The second mechanism employed in short-distance pruning events is 
axon retraction. During this process, axons form a large, distal, vesicle filled 
retraction bulb that retracts from the area it previously innervated while remaining 
intact (Neukomm and Freeman, 2014)(Figure 1.1B). Retraction is mainly carried 
out by reorganization of axonal actin filaments in a RhoA GTPase-dependent 
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process that leaves the microtubule structure intact and allows distal to proximal 
transport of vesicles from the retracting edge of the axon (Saxena and Caroni, 
2007). The most notable example of retraction is pruning of the infrapyramidal 
bundle (IPB), a hippocampal mossy fiber tract, in the central nervous system 
(CNS). Morphological studies in mouse demonstrate that Semaphorin 3A and 3F 
signal through their receptors Plexin-A3 and Neuropilin-2 to induce axon 
retraction during the first 2 months of postnatal life,(Bagri et al., 2003; Cheng et 
al., 2001; Luo and O’Leary, 2005; Vanderhaeghen and Cheng, 2010). Two-
photon time-lapse studies have also demonstrated axon retraction in developing 
layer 1 cortical interneurons in mice (Portera-Cailliau et al., 2005). 
The primary method employed in pruning of large-scale axonal 
projections, and the mechanism that this thesis will focus on, is axon 
degeneration (Luo and O’Leary, 2005; Neukomm and Freeman, 2014)(Figure 1.1 
D). Axonal projections eliminated in this manner initially display swelling before 
ultimately fragmenting and being engulfed by cells in the area, including 
macrophages (Saxena and Caroni, 2007; Schuldiner and Yaron, 2014). This 
section will discuss two striking examples of this paradigm in the mammalian 
CNS and one in the developing fly. Degenerative pruning in the PNS, which 
serves as a useful experimental model, will be discussed in a later section.  
Over the first postnatal week in the developing mammalian nervous 
system, axons of retinal ganglion cells (RGCs) initially project across the entire 
length of the Superior Colliculus (SC) before ultimately pruning back to an 
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anterior termination zone in a degenerative process (Luo and O’Leary, 2005; 
Saxena and Caroni, 2007; Vanderhaeghen and Cheng, 2010). Elegant studies 
have demonstrated that this event is orchestrated, in part, by graded expression 
of the repellant guidance cues Ephrins and their receptors the Ephs, in addition 
to coordinated waves of electrical activity, resulting in observable fragmentation 
of the exuberant axonal projections (Hindges et al., 2002; Hoopfer et al., 2006; 
McLaughlin et al., 2003a; 2003b; Yates et al., 2001). Of note, key components of 
the apoptotic program including Caspase-3, Caspase-6, and the p75 receptor 
relative DR6 are partially responsible for this pruning (Nikolaev et al., 2009; 
Olsen et al., 2014; Simon et al., 2012); a point that will be dealt with in greater 
detail in the following sections. 
Pruning of layer V cortical neuron projections in mammals provides 
another classic example of degenerative pruning. In the adult, axons from 
specific layer V cortical populations project to areas in the brain as a function of 
their identity, with visual cortex neurons projecting to the SC and motor cortex 
neurons projecting to the spinal cord (Luo and O’Leary, 2005; Saxena and 
Caroni, 2007). However, early in development they make connections broadly, 
meaning that both visual and motor cortex neurons project to both the SC and 
spinal cord before improper connections are pruned through degeneration 
(Hoopfer et al., 2006). Given that only a specific portion of the complete axonal 
arbor is removed, one might assume that all cellular factors necessary to initiate 
and execute pruning would be located in the neuronal process targeted for 
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degeneration. However, although only a specific axonal branch is removed in this 
process, it depends on the activity of a transcription factor, Otx1, which moves 
from the cytoplasm to the nucleus during the window when degeneration is 
initiated (Weimann et al., 1999). Furthermore, heterotopic transplantation of 
visual cortex neurons to the motor cortex and vice versa results in the 
transplanted neurons maintaining the collateral appropriate for the new region, 
further implicating the cell body as a potentially critical arbiter in shaping these 
connections (O'Leary and Stanfield, 1989; Stanfield and O'Leary, 1985). 
A transcriptional mechanism is also involved in the pruning of γ neuron 
projections in the mushroom body (MB) of developing Drosophila resulting in 
fragmentation and clearing of these axons (Watts et al., 2003). During 
metamosphosis, larval specific axonal projections are pruned in a mechanism 
acting through the hormone Ecdysone, signaling through Ecdysone Receptor-B1 
expressed by γ neurons and upregulated in a manner dependent on TGF-β 
signaling (Lee et al., 2000; Schuldiner and Yaron, 2014; Zheng et al., 2003). The 
transcription factor Sox14 serves as a critical target of Ecdysone Receptor 
signaling in the pruning of these axons. The pruning of the dendritic arbor of fly 
sensory dendritic arborization (da) neurons is also dependent on this 
transcriptional mechanism (Kirilly et al., 2009). Intriguingly, as in SC axon 
pruning, caspases are crucial mediators of dendrite pruning, suggesting an 
evolutionarily conserved mechanism for removal of some neuronal processes. 
However, pruning of MB axons does not seem to involve these proteases, 
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pointing to the existence of alternative degenerative pathways (Awasaki et al., 
2006; Kuo et al., 2006; Williams et al., 2006). 
 
Axon degeneration in injury and disease 
 In 1850 Augustus Waller observed that the distal segment of axons that 
are physically severed from their cell body fragment and ultimately degenerate 
(Figure 1.1E). Initially thought to be a passive process, this view was upended by 
the discovery of the Wallerian degeneration slow (Wlds) mouse, which displayed 
drastically delayed degeneration of the axon after physical insult, indicating an 
active molecular mechanism was at play (Coleman and Freeman, 2010; Lunn et 
al., 1989). The Wlds gene, a result of a spontaneous dominant mutation, 
produces a fusion protein containing the coding region of the NAD+ synthesizing 
enzyme NMNAT, indicating it plays a role in regulating cellular metabolism 
(Coleman, 2005). More recently, Drosophila sterile a/Armadillo/Toll-interleukin 
receptor homology domain protein (dSarm) and its mammalian ortholog Sarm1 
were shown to play a critical role in axon degeneration after injury or chemical 
insult, highlighting an endogenous and evolutionarily conserved mechanism in 
both in vitro and in vivo systems (Osterloh et al., 2012; Yang et al., 2015). 
Further studies have shown that the Drosophila E3 ubiquitin ligase highwire (Hiw) 
and its mammalian homolog Phr1, as well as MAPK and JNK signaling, are 
involved in a pathway that culminates in axonal energy deficits, a rise in 
intracellular calcium, activation of the calcium dependent protease calpain, and 
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ultimately Wallerian degeneration (Babetto et al., 2013; Coleman and Freeman, 
2010; Wang et al., 2012; Xiong et al., 2012; Yang et al., 2015; 2013). 
 In contrast with several forms of developmental axon degeneration, 
Wallerian degeneration is caspase independent (Finn et al., 2000; Simon et al., 
2012; Vohra et al., 2010). Wallerian degeneration also does not seem to be 
critical for developmental axon pruning in mammals, as Wlds does not delay or 
prevent developmental pruning in the SC or layer V cortex (Hoopfer et al., 2006). 
Furthermore, neither Wlds nor dSarm play a role in MB axon pruning in 
Drosophila (Hoopfer et al., 2006; Osterloh et al., 2012). Finally, the physical 
separation of the axon from the cell body precludes involvement of somatic 
signaling and transcription programs from being involved in this process, a 
notable difference from the developmental degeneration. 
 Axon degeneration is a prominent feature of many neurodegenerative 
diseases, which often display a “dying back” of axons preceding neuronal cell 
body death (Höke, 2006; Luo and O’Leary, 2005). Particularly in human 
peripheral neuropathies, but also documented in motor neuron disease, 
Alzheimer’s, and Parkinson’s disease, affected neurons are characterized by 
degeneration beginning at their distal tip that proceeds proximally toward the cell 
body (Raff, 2002; Saxena and Caroni, 2007). This phenomenon has been 
compellingly demonstrated in several mouse models of neurodegenerative 
disease including Huntington’s disease, Alzheimer’s disease, and Amyotrophic 
Lateral Sclerosis (ALS) (Fischer et al., 2004; Li et al., 2001; Tsai et al., 2004)). 
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One may posit that this phenotype may be a secondary consequence of loss of 
nourishing factors from degenerating cell bodies. However, several mouse 
disease models and examples of human motor neuron diseases result from 
disruption of the dynein-dynactin complex, which regulates retrograde transport. 
In these diseases anterograde transport is preserved, indicating retrograde 
communication from the axon to the cell body is crucial for axon maintenance 
(Perlson et al., 2010). The factors involved in this signaling, and what role the cell 
body plays, remain to be elucidated. 
 The mechanisms involved in axon degeneration during neurodegenerative 
disease vary. For example, crossing a mouse model of progressive motor 
neuropathy (pmn) to Wlds significantly delays disease progression, but Wlds does 
not provide any protection in superoxide dismutase 1 (SOD1) transgenic mouse 
models of ALS (Ferri et al., 2003; Vande Velde et al., 2004). In other pathological 
conditions such as Huntington’s disease, Alzheimer’s disease, and stroke, 
components of the apoptotic pathway, specifically caspases, appear to play a 
significant role (Akpan et al., 2011; Wang et al., 2015). Recent work also shows 
that mice with a knockout of an anti-apoptotic Bcl-2 gene, Bcl-w, exhibit a 
progressive loss of epidermal nociceptive fibers without concurrent cell body loss, 
akin to a disease known as small fiber sensory neuropathy (Courchesne et al., 
2011). The involvement of apoptotic proteins in this context mirrors the 
developmental pruning described in several processes above, such as pruning of 
SC axons, suggesting that developmental and pathological pruning may share a 
	   11 
common molecular mechanism, albeit one that is erroneously activated in 
disease.  Importantly, how the neuron determines which degenerative 
mechanism to employ and what specific intracellular signals are engaged in that 
process are still undetermined.  
Developmental pruning in the PNS and the neurotrophic hypothesis 
 During the early stages of embryonic development, sensory neurons in 
mouse and chick experimental systems extend afferents to the periphery in 
excess. As development proceeds, over 50% of the extended axons and their 
cell bodies are culled (Oppenheim, 1991). Pioneering work done by Viktor 
Hamburger and Rita-Levi Montalcini investigating the biological mechanism of 
this phenomenon led to the development of the neurotrophic hypothesis, which 
states that axons of developing neurons compete for limited amounts of target 
derived neurotrophic factors. According to this hypothesis, those afferents that 
make the proper connections are preserved while those that are mis-targeted or 
outcompeted are fated to degenerate (Davies, 1996; Levi-Montalcini, 1987). 
Groundbreaking experiments led to the isolation of the first neurotrophic factor, 
nerve growth factor (NGF), with further studies identifying additional 
neurotrophins, including brain-derived neurotrophic factor (BDNF) and 
neurotrophin-3 (NT-3) (Huang and Reichardt, 2001). 
The critical importance of NGF for pruning of sensory axons from neurons 
in the dorsal root ganglia (DRG) has been amply demonstrated, as reducing 
target derived NGF either by limb bud extirpation or treatment of developing 
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embryos with NGF anti-serum drastically depletes DRG neurons. Conversely, 
injection of NGF reduces naturally occurring neuronal death (Davies, 1996; 
Hamburger and Yip, 1984; Johnson et al., 1980; Levi-Montalcini, 1987). Further, 
genetic deletion of NGF resulted in a 70% depletion of neurons in mouse lumbar 
DRGs, whereas transgenic overexpression in mouse epidermis yielded 
enhanced DRG survival and skin innervation, providing a robust confirmation of 
the necessity of target derived neurotrophins in maintaining these projections 
(Albers et al., 1994; Crowley et al., 1994). 
 In line with developmental pruning in the SC, degeneration of NGF 
responsive sensory neurons is mediated by an apoptotic mechanism. Deletion of 
the apoptotic effector Bax drastically reduces the in vivo cell death seen in this 
paradigm and studies using light-level microscopy have shown a significant 
increase in small unmyelinated fibers in sciatic nerves of adult Bax knockout mice 
(Deckwerth et al., 1996; Sun et al., 2003; White et al., 1998). Coincident with the 
period of peak developmental pruning during embryogenesis, markedly 
increased levels of cleaved Caspase-3, a key effector protease in apoptosis, are 
observed in both DRG cell bodies and axons using the newly developed iDISCO 
whole mount immunolabeling and volume imaging protocol (Renier et al., 2014).  
 High affinity binding of NGF to the receptor tyrosine kinase TrkA induces 
its dimerization and autophosphorylation leading to recruitment and activation of 
a host of local and retrograde signaling cascades necessary for the survival and 
differentiation of neurons (Reichardt, 2006; Zweifel et al., 2005) (Figure 1.2A). 
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The most critical pathways activated by NGF binding to TrkA are the PI3K/Akt 
pathway and the MEK/ERK (also called the MEK/MAPK) pathway (Kaplan and 
Miller, 2000). PI3K/Akt signaling is required for neurotrophin induced neuronal 
growth and survival, whereas MEK/MAPK signaling is more closely involved in 
neuronal differentiation, only serving as a minor player in survival (Atwal et al., 
2000; Kaplan and Miller, 2000; Kuruvilla et al., 2000; Mazzoni et al., 1999). 
 A particularly notable aspect of this system is that NGF binding to TrkA 
results in endocytosis of the activated receptor, which is then trafficked in a 
retrograde fashion back to the cell body as a signaling endosome (Zweifel et al., 
2005) (Figure 1.2B). This process has been elegantly visualized in vitro by David 
Ginty and colleagues using NGF responsive sensory axons from a mouse 
expressing a knock-in of a FLAG-tagged TrkA (Sharma et al., 2010). When NGF 
responsive neurons from these mice are grown in compartmented chambers 
(described below) where only the distal axon is treated with NGF, TrkA signaling 
endosomes can be observed migrating down the axon to the cell body by 
immunofluorescence (Harrington et al., 2011). Signaling endosomes are 
transported to the cell body by dynein dependent microtubule transport and 
disruption of this process, such as can be achieved by overexpression of 
dynamitin in vitro, leads to neuronal death (Heerssen et al., 2004). Inhibition of 
TrkA or PI3K signaling specifically in either cell bodies or axons of sympathetic 
neurons results in cell death, further pointing to the necessity of retrograde 
signaling for neuronal survival (Kuruvilla et al., 2000; Ye et al., 2003). Intriguingly, 
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although studies have examined the effects of TrkA inhibition on neuronal cell 
body death, they have not examined the ability of axons to survive when TrkA 
signaling is specifically inhibited in cell bodies, which could yield new insights into 




Figure 1.2 NGF signals through the receptor tyrosine kinase TrkA (A) NGF 
binding to TrkA induces dimerization and autophosphorylation. Multiple 
downstream signaling events occur including activation of MEK/ERK and 
PI3K/Akt pathways. (Reprinted with permission from (Chao, 2003)) (B) NGF-TrkA 
signaling complexes internalize to form signaling endosomes, which are 
transported by the Dynein-dynactin complex back to the cell body in a retrograde 
fashion. (Reprinted with permission from (Zweifel et al., 2005)) 
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 Developmental axon degeneration of sensory neurons in the PNS is 
particularly vital to the questions raised in this thesis due to the existence of a 
powerful in vitro system that can model many aspects of this process. Mouse 
DRG explants can be cultured in the presence of NGF, which induces axon 
outgrowth from TrkA expressing neurons. The explants can then be deprived of 
NGF through application of a function-blocking NGF antibody, resulting in axon 
degeneration and somatic apoptosis (Figure 1.3). Importantly, the segregation of 
cell bodies and axons seen in vivo can be recapitulated in vitro by growing 
neurons in compartmented chambers (also called Campenot chambers), allowing 
for individual treatment of either the cell body or axon compartment, which are 
separated by a grease barrier (Campenot, 1977; 1982; Campenot et al., 
1991)(Figure 1.4). Using this system, Robert Campenot demonstrated that local 
trophic deprivation of distal axons induces their degeneration, even when cell 
bodies are still treated with NGF. Furthermore, specific NGF deprivation of cell 
bodies does not induce degeneration of distal axons still bathed in NGF media, 
highlighting a critical role for retrograde signaling from distal axons (Campenot, 
1977; 1982). Several studies also claim that these chambers can be used to 
induce distal axon degeneration that does not result in neuronal cell body death 
(Campenot, 1977; Mok et al., 2009; Ghosh et al., 2011). However, it is difficult to 
ascertain if this is truly the case. Approximately 120,000 cells are typically plated 
in a Campenot chamber (see methods), whereas ~1500 axons are typically 
observed crossing the grease barrier in each axonal compartment, meaning a 
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vast majority of neurons do not project axons outside of the central cell body 
compartment. Without specifically labeling the neurons whose axons grew across 
the grease barrier, it is unclear if cell bodies are truly preserved after distal NGF 
withdrawal. Importantly, although there is evidence that pruning of BDNF 
dependent sensory axons in the mammary gland can occur without neuronal 
death, similar data regarding NGF responsive axons in vivo is lacking, making 
the existence of this phenomenon a key unanswered question in the field (Liu et 
al., 2012).  
 
 
Figure 1.3 Whole explant DRG culture system DRGs from embryonic day 12.5 
mouse can be cultured in the presence of NGF, resulting in axon outgrowth (left 
panel). Application of an NGF function-blocking antibody causes axons to 
degenerate, resulting in fragmentation the Tubulin cytoskeleton (right panel). 










Figure 1.4 DRG culture in compartmented Campenot chambers. (A) 
Dissociated DRGs placed in the center cell compartment extend axons 
underneath a grease barrier, growing along lanes created by scratching the plate 
with a pin rake. Cell bodies and axons are fluidically isolated and can be 
subjected to individual treatments. (Reprinted with permission from (Zweifel et al., 
2005)). (B) Degeneration of distal axons is induced adding NGF function-blocking 
antibody specifically to the axonal compartment. Axon degeneration visualized 








Mechanisms of apoptosis 
As mentioned above, apoptotic mechanisms appear to play a fundamental 
role in axon degenerations in several contexts. More broadly a role for apoptotic 
cell death is an essential feature of animal development for species ranging from 
the nematode worm C. elegans to humans (Fuchs and Steller, 2011). The central 
executioners of this process are a family of evolutionarily conserved cysteine 
proteases, the caspases (Hengartner, 2000). Initially synthesized as 
proteolytically inactive zymogens, diverse apoptotic stumuli can trigger their 
processing into mature, active, heterotetramers (Hengartner, 2000). Apoptosis 
involves two distinct sets of caspases; namely the initiator caspases, Caspase-8 
and Caspase-9, and the executioner caspases, Caspase-3, -6, and -7. Initiator 
caspases serve to cleave and activate executioner caspases, which then 
proceed to cleave a wide array of intracellular substrates resulting in 
fragmentation of the cell before cell remnants are ultimately engulfed by 
phagocytosis (Thornberry and Lazebnik, 1998). 
Apoptosis can be triggered by either the death-receptor dependent 
“extrinsic” pathway or the mitochondrial “intrinsic” pathway (Figure 1.5). In the 
extrinsic pathway, death activating ligands bind to death receptors such as Fas 
and tumor necrosis factor receptor 1 (TNFR1), initiating recruitment of death 
effector domains to the intracellular death domains of these transmembrane 
receptors (Vila and Przedborski, 2003). Death effector domains recruit the central 
initiator caspase of the extrinsic pathway, Caspase-8, which becomes activated 
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as the low intrinsic protease activity of the zymogen is sufficient to induce 
cleavage and activation due to the drastically increased local concentration 




Figure 1.5 Schematic of apoptotic pathway. In the “intrinsic pathway” cellular 
stress signals induce Bax/Bak translocation to the mitochondria, releasing 
cytochrome c, which leads to activation of Caspase-9 and downstream effector 
caspases. This process is regulated by pro- and anti-apoptotic Bcl-2 family 
members. In the “extrinsic pathway”, stress signals from the TNFR family of 
receptors lead to activation of Caspase-8 which goes on to activate effector 
caspases. As indicated, the extrinsic pathway can feed into the intrinsic pathway. 
Speculative links (marked by a “?”) are also shown. (Illustration by David Simon). 
	   20 
 
The mitochondrial or “intrinsic” pathway integrates multiple intracellular 
cues leading to oligimerization of the pro-apoptotic protein Bax, resulting in 
mitochondrial outer membrane permeabilization (MOMP) (Figure 1.5). 
Permeabilized mitochondria release cytochrome c into the cytoplasm, forming the 
apoptosome in conjunction with Apaf-1 and leading to the cleavage and 
activation of the initiator caspase, Caspase-9 (Hengartner, 2000; Vila and 
Przedborski, 2003). As with Caspase-8 in the extrinsic pathway, catalytically 
active Caspase-9 cleaves downstream effector caspases, inducing their protease 
ability. Importantly, MOMP in mammals also releases the proteins Smac and 
DIABLO which can bind to and inhibit a class of proteins known as inhibitor of 
apoptosis proteins (IAPs), which in turn can bind to and inhibit the catalytic 
activity of Caspase-3 (Salvesen and Duckett, 2002).  
 
Regulation of the mitochondrial apoptotic pathway by the Bcl-2 family 
 The oligimerization of Bax (and the closely related protein Bak), which 
causes MOMP, is regulated by the Bcl-2 family of proteins, which contains both 
pro- and anti- apoptotic members (Adams and Cory, 1998; Youle and Strasser, 
2008) (Figure 1.5). The five anti-apoptotic Bcl-2 family members  – Bcl-2, Bcl-xL, 
Bcl-w, Mcl-1, and A1 – can bind to and inhibit Bax oligimerization through 
interaction between the Bcl-2 homology (BH) domains contained in each protein, 
forming heterodimers (Adams and Cory, 1998; Ghiotto et al., 2009). The seven 
pro-apoptotic or “BH3 only” family members – Bid, Bim, Puma, Bad, Noxa, Hrk, 
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and Bmf – can inhibit the activity of the anti-apoptotic members and promote Bax 
oligimerization (Youle and Strasser, 2008). 
Two independent mechanisms have been proposed to explain the ability 
of BH3 only proteins to induce apoptosis, known as the direct and indirect 
activation models (Adams and Cory, 2007). In the direct activation model, the 
seven BH3 proteins are grouped into activators and sensitizers. Activators, such 
as Bid, Bim, and Puma, are proposed to bind directly to Bax (or Bak), resulting in 
a conformational change that promotes olgimerization. In this model, the primary 
function of sensitizers, such as Bad and Noxa, is to bind to anti-apoptotic Bcl-2 
family members, releasing activator proteins from their inhibitory binding (Adams 
and Cory, 2007). Evidence for this model is seen using an in vitro mitochondrial 
permeabilization assay, where Bid, Bim, and Puma are able to induce MOMP 
when incubated with isolated mitochondria in the presence of Bax, whereas 
incubation with other BH3 proteins or Bax alone does not yield cytochrome c 
release (Cartron et al., 2004; Letai et al., 2002). Support for this model is also 
seen in vivo, as mice with a triple genetic knockout of Bid, Bim, and Puma have 
cell death phenotypes similar to Bax;Bak double knockouts, positioning them as 
essential activators of these proteins that cannot be compensated for by the 
remaining family members (Ren et al., 2010). 
The indirect activation model proposes that initiation of apoptosis by Bax 
oligimerization is the default state in cells, but that this activity is inhibited by 
binding to anti-apoptotic Bcl-2 family members such as Bcl-xL. In this paradigm, 
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the sole function of BH3 only proteins is to disrupt these inhibitory heterodimers 
by binding to anti-apoptotic proteins and releasing Bax (Adams and Cory, 2007). 
Bid, Bim, and Puma are positioned as the most potent effectors because they 
bind all anti-apoptotic Bcl-2 family members, whereas the other BH3 only 
proteins do not (Chen et al., 2005a). Supporting this view, mutation of the Bax 
binding domain of Bim and Bid does not suppress their ability to induce cell death 
in vitro (Willis et al., 2007).  Furthermore, co-expression of Noxa and Bad can 
induce death of Bid;Bim double knockout cells where Puma was also knocked 
down, although it is possible that some residual Puma activity could account for 
the apoptotic response (Willis et al., 2007). Given that there is experimental 
evidence to support both models, it is possible that different models apply to 
different cell types or may be important in different contexts within the same cell 
(Shamas-Din et al., 2013). 
 Several mechanisms of transcriptional and post-translational modification 
regulate the activity of BH3 only proteins (Puthalakath and Strasser, 2002). The 
transcription factors p53, c-jun, and members of the FOXO family strictly regulate 
the levels of Bid, Bim, and Puma (Schuler and Green, 2005; Whitfield et al., 
2001; Wong et al., 2005; Yu and Zhang, 2009; Zhang et al., 2011). Hrk is 
additionally under tight transcriptional control (Puthalakath and Strasser, 2002). 
Phosphorylation events are also critical, with Bad and Bim activity being 
regulated by Akt and JNK signaling respectively (Datta et al., 1997; Putcha et al., 
2003). Finally, the full-length version of Bid has only weak pro-apoptotic activity, 
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requiring proteolytic cleavage to produce the more apoptotically active protein 
tBid. Interestingly, this provides a mechanism whereby the extrinsic pathway can 
feed back on the intrinsic pathway through Caspase-8 mediated cleavage of Bid 
(Li et al., 1998; Luo et al., 1998; Youle and Strasser, 2008). 
 
The role of Puma in the mitochondrial apoptotic pathway 
 Puma is a pro-apoptotic Bcl-2 family member classically regulated by p53 
mediated transcriptional up-regulation, hence its name p53 up-regulated 
modulator of apoptosis (Yu and Zhang, 2009). Independently discovered by three 
groups in 2001 (Han et al., 2001; Nakano and Vousden, 2001; Yu et al., 2001), 
this protein, which contains a BH3 domain and a C-terminal mitochondrial 
localization sequence (Hikisz and Kiliańska, 2012), is now known to play a critical 
role in initiation of the mitochondrial apoptotic program in response to a diverse 
set of cellular stressors. In the most widely studied mechanism of Puma action, 
Puma is initially transcribed only at very low levels (if at all), but DNA damage 
triggers nuclear movement of p53 which then transactivates the Puma locus 
(Wang et al., 2007; Yu et al., 2001). This causes a dramatic increase in Puma 
levels within the cell, which induces Bax oligimerization and MOMP, ultimately 
leading to activation of downstream caspases and the death of the cell.  
 In addition to the classic, p53-mediated mechanism, p53-independent 
mechanisms of Puma induction are shown to function in several other contexts. 
For example, Puma is central to cell death following growth factor withdrawal, ER 
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stress, or ischemia/reperfusion in several in vitro and in vivo systems (Yu and 
Zhang, 2009). In a majority of these examples, transcriptional regulation of Puma 
occurs independently of p53, instead being induced by transcription factors such 
as Foxo3a (You et al., 2006), p73 (Ming et al., 2008), c-jun (Zhao et al., 2012),  
or E2F1 (Hershko and Ginsberg, 2004). 
Although there is universal agreement that Puma induces cell death 
through the mitochondrial apoptotic pathway, whether it does this as a direct or 
indirect activator, is still debated. In favor of its role as a direct activator, Puma 
overexpression can induce a Bax conformational change and trigger MOMP in 
colorectal cancer cells (Yu et al., 2003) and can directly interact with Bax in in 
vitro mitochondrial permeabilization assays (Cartron et al., 2004). However, the 
fact that deletion of the C-terminal hydrophobic domain of Puma, which is 
essential for binding to Bax, did not abrogate its ability to induce apoptosis (Yee 
and Vousden, 2007), would argue for a more indirect role. Regardless, the ability 
of Puma to strongly bind to all anti-apoptotic Bcl-2 family members and disrupt 
their interaction with Bax (Chen et al., 2005a), positions Puma as a potent 
inducer of apoptosis. 
Once thought to only be transcriptionally regulated, recent studies have 
shown that Puma is also subject to post-translational regulation. Phosphorylation 
of Puma on serine-10 reduces it’s stability and expression of a Puma mutant 
containing a serine to alanine mutation at this residue (S10A) which renders it 
unable to be phosphorylated, increases its apoptosis-inducing effect in HeLa 
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cells (Fricker et al., 2010). The increased apoptotic potential of S10A Puma was 
not a result of altered binding to anti-apoptotic Bcl-2 family members, but appears 
to be a result of reduced protein turnover when compared to phosphorylated 
Puma. Interestingly, the increased turnover of phosphorylated Puma is not 
mediated by caspases or macroautophagy, but is instead dependent on 
proteasome activity (Fricker et al., 2010). This is notable because Puma does not 
contain any lysine residues to which ubiquitin can be conjugated to target the 
protein for degradation by the proteasome. The mechanism by which this 
phosphorylation-induced proteasome-dependent Puma degradation occurs, has 
yet to be elucidated. 
Puma is also unique among pro-apoptotic family members in its ability to 
trigger Bax activation in a mechanism involving cytosolic p53 in a non-
transcriptional role. Like Bid, Bim, and Puma, p53 has the ability to induce Bax 
activation and MOMP in in vitro mitochondrial permeabilization assays (Chipuk et 
al., 2004). This activity of p53 is directly inhibited by binding to Bcl-xL, but in 
mouse embryonic fibroblasts treated with UV irradiation, nuclear p53 induces 
increased Puma expression which bind to Bcl-xL and frees cytosolic p53 from its 
inhibitory effects (Chipuk et al., 2005). While one might argue that this effect was 
carried out exclusively by Puma, expression of a mutant form of Bcl-xL that could 
bind to p53, but not any pro-apoptotic Bcl-2 family members including Bax or 
Puma, protected these cells from apoptosis, arguing for a direct role of p53 in 
Bax activation (Chipuk et al., 2005). Notably, Puma is the only pro-apoptotic Bcl-
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2 family member capable of disrupting the binding between p53 and Bcl-xL (Follis 
et al., 2013). 
 
The mitochondrial apoptotic pathway in axon degeneration 
 Numerous components of the mitochondrial apoptotic pathway have been 
shown to play a significant role in neuronal death in several contexts. Genetic 
deletion of Apaf-1, a central component of the apoptosome formed after MOMP 
in the mitochondrial apoptotic pathway, protects neurons from apoptosis after 
NGF withdrawal (Wright et al., 2006).  Overexpression of Bcl-2 in mice results in 
increased numbers of facial and RGC neurons during development and Bcl-2 
overexpression in chicken DRGs protects against neurotrophin withdrawal 
induced apoptosis (Gagliardini et al., 1994; Martinou et al., 1994). Furthermore, 
genetic deletion of Bcl-xL in mice results in catastrophic death of postmitotic 
neurons in the brain, spinal cord, and DRGs, with neuronal specific deletion of 
Mcl-1 having a similar effect (Arbour et al., 2008; Motoyama et al., 1995).  
 Neuronal death both in vivo during development and in vitro after NGF 
withdrawal is Bax-dependent, and Caspase-3 activation is drastically reduced in 
embryonic DRGs in Bax knockout mice (Deckwerth et al., 1996; Renier et al., 
2014; White et al., 1998). In accordance with a central role for Bax in neuronal 
death, several BH3 only family members have been implicated in apoptotic 
initiation. Specifically, roles for Bad, Bim, Puma, and Hrk have been 
demonstrated in neuronal apoptosis after growth factor withdrawal or DNA 
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damage (Ambacher et al., 2012; Datta et al., 1997; Imaizumi et al., 2004; Jean et 
al., 2013; Putcha et al., 2003; Wong et al., 2005; Wyttenbach and Tolkovsky, 
2006).  
 Despite the abundant evidence that the mitochondrial apoptotic pathway 
induces caspase dependent neuronal death in multiple systems, its involvement 
in axon degeneration was largely discounted until recently. As described above, 
injury-induced Wallerian degeneration is not dependent on caspases or Bax/Bak 
activation and chemical inhibition or siRNA knockdown of canonical caspases did 
not protect axons from degenerating in other contexts (Finn et al., 2000; Nikolaev 
et al., 2009; Vohra et al., 2010; Whitmore et al., 2003). However, recent studies 
using knockout mice instead of knockdown have shown that the initiator caspase, 
Caspase-9, and the executioner caspases, Caspase- 3 and Caspase-6, play a 
key role in axon degeneration of PNS sensory neurons after trophic factor 
withdrawal (Cusack et al., 2013; Nikolaev et al., 2009; Simon et al., 2012). 
Recent evidence also indicates that a common mechanism for axon 
degeneration may be shared between the in vitro NGF withdrawal paradigm and 
developmental axon pruning in vivo, because developmental pruning of SC 
axons, a trophic factor independent process, also partially depends on Caspase-
3 and Caspase-6 (Simon et al., 2012). 
Bax is essential for NGF withdrawal induced axon degeneration in whole 
explant cultures as well as in Campenot chambers, highlighting a central role for 
the mitochondrial apoptotic pathway (Nikolaev et al., 2009). This connection is 
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further solidified by the fact that Bcl-xL overexpression blocks axon degeneration 
after NGF withdrawal (Vohra et al., 2010). Genetic deletion of Bcl-w also 
accelerates axon degeneration in this system in vitro, while in vivo these mice 
exhibit a progressive loss of epidermal nociceptive fibers without concurrent cell 
body loss, akin to a disease known as small fiber sensory neuropathy (Cosker et 
al., 2013; Courchesne et al., 2011). This could point to a role for the classical 
mitochondrial apoptotic pathway in axon degeneration associated with some 
disease models.  
Several upstream factors have been identified in the molecular pathway 
leading to axon degeneration in the NGF withdrawal paradigm, including the JNK 
interactor Dual lysine kinase (DLK) and death receptor 6 (DR6) (Huntwork-
Rodriguez et al., 2013; Nikolaev et al., 2009; Ghosh et al., 2011).  However, the 
full repertoire of factors operating between the cessation of neurotrophin 
signaling and Bax activation remains to be described. Similarly, although 
application of ABT-737, an inhibitor of Bcl-2, Bcl-XL, and Bcl-w, can trigger axon 
degeneration, the role of BH3 proteins and the mechanism regulating their action 
in this system is completely unknown (Simon et al., 2012). This question is a 
central component of this thesis. 
 
Compartmentalization of factors in axon degeneration 
 In conjunction with incomplete knowledge of the full set of effectors in 
axon degeneration, the mechanisms leading to their activation are also unknown, 
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as is the site of initiation of the degenerative process. The accepted model 
contends that trophic deprivation of distal axons initiates a degenerative pathway 
contained exclusively within the axon itself, completely independent of the soma. 
A primary driver of this view is a study showing that while JNK signaling is an 
essential regulator of axon degeneration and neuronal apoptosis after NGF 
withdrawal, neurons containing a genetic deletion for the transcription factor c-
jun, a JNK target, are only protected from apoptosis but not axon degeneration 
(Ghosh et al., 2011). Thus, the view emerged that local signaling events in 
distally deprived axons represented a process independent of cell body death. 
Zebrafish studies using an indirect reporter of caspase activation revealed in vivo 
caspase activation at axonal branch points, but not in the cell body, and 
Drosophila studies showing dendrite specific caspase activity in da neuron 
pruning were also taken as evidence for local degenerative signaling (Campbell 
and Okamoto, 2013; Williams et al., 2006). 
 Mechanisms directing the spatial restriction of degenerative signaling 
within the axon have also been proposed. Although neurons lacking Apaf-1 are 
protected from apoptosis following NGF withdrawal, a recent study found that 
genetic deletion of Apaf-1 did not protect axons from local deprivation in 
microfluidic chambers, hinting at the existence of separate cell body and axon 
mechanisms of caspase activation (Cusack et al., 2013). In addition, XIAP 
appears to prevent caspase activation in cell bodies when distal axons are 
subject to trophic deprivation and local initiation of caspase activity in dendrites 
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using photostimulation of Mito-KillerRed did not spread back to cell bodies unless 
neurons were treated with IAP or proteasome inhibitors (Erturk et al., 2014; 
Unsain et al., 2013). Taken together, these results paint a picture of local 
signaling causing degenerative caspase activation that is actively restricted from 
the cell body by several factors. 
 Although these results are compelling, several lines of evidence are at 
odds with the prevailing view of a local pro-degenerative program contained 
exclusively within axons. As discussed above, developmental pruning of MB γ 
neuron projections and da neurons dendrites in Drosophila depends on a 
transcriptional cascade mediate by ecdysone receptor signaling (Lee et al., 2000; 
Watts et al., 2003; Zheng et al., 2003). Pruning of mammalian layer V cortical 
projections is similarly dependent on the transcription factor Otx1, highlighting an 
active role for somatic signaling in both of these processes (Weimann et al., 
1999). Recent in vitro studies have also implicated somatic signaling as crucial 
for caspase-dependent axon degeneration after trophic deprivation. Axons 
severed from their cell bodies but protected from Wallerian degeneration by 
genetic deletion of Sarm1 do not demonstrate Caspase-3 activation and 
subsequent axon degeneration in response to NGF withdrawal (Gerdts et al., 
2013). Further, application of a transcriptional inhibitor or inhibiting the kinase 
GSK3β specifically in the cell body compartment of Campenot chambers results 
in a robust protection of axons after local trophic deprivation (Chen et al., 2012). 
These results call into question whether the degenerative signal is contained 
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exclusively within the axon itself or whether the cell body plays an active, and 
essential, role in initiating axon degeneration. The effort to resolve this 
controversy is a central pillar of my thesis work. 
Perspective and overview of the thesis project 
The work detailed in this thesis originally began with the goal of isolating 
the specific Bcl-2 family members involved in regulating Bax activation upstream 
of caspase-dependent axon degeneration after trophic deprivation (TD). The 
initial approach was focused on conducting a knockout screen looking for in vitro 
axon degeneration phenotypes in knockout mice of pro- and anti-apoptotic Bcl-2 
family members. Specifically, the rationale was that when examining whole 
explant cultures subjected to TD, deletion of pro-apoptotic (BH3) members 
involved in the degenerative process would exhibit a delayed degeneration 
phenotype, whereas deletion of critical anti-apoptotic Bcl-2 family members 
would accelerate degeneration. Once these factors were identified, I sought to 
examine their relationship to each other and determine the mechanism by which 
they were regulated. The result of these experiments was the identification of 
Puma as the primary regulator of axon degeneration after TD in DRG neurons 
(detailed below), but several pieces of data inspired a change in the focus of the 
project. 
Experiments done by Yuya Yamagishi in the Tessier-Lavigne lab showed 
that calcium chelation had differential effects on axon degeneration depending on 
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the context. As described above, Wallerian degeneration is mediated by the 
calpains, a family of calcium dependent proteases. As a result, addition of the 
calcium chelator EGTA prevents the influx of calcium that is required for the 
activation of calpains after cutting, delaying axon degeneration. Strikingly, the 
ability of EGTA to prevent calcium influx into the cell, which prevents Wallerian 
degeneration, also produces a stress response in DRG explant cultures that 
results in caspase activation in axons still connected to their cell bodies (Figure 
1.6). Importantly, Caspase-3 could only be activated in axons when they were 
connected to the cell body, indicating an active somatic role in caspase-
dependent axon degeneration. This result was mirrored by experiments 
discussed above whereby NGF withdrawal did not cause Caspase-3 activation in 
severed axons protected from Wallerian degeneration by genetic deletion of 
Sarm1 (Gerdts et al., 2013). As that result was obtained using 
immunofluorescence, I also probed this phenomenon with Western blotting; a 
more sensitive assay that could identify low level Caspase-3 activity. 
Concordantly, I found that severed axons protected from Wallerian degeneration 
by EGTA addition did not show evidence of Caspase-3 activation after TD, while 
intact axons did (Figure 1.7). Collectively these data pointed towards active 
control of axon degeneration by signaling from the cell body, despite other work 
from the lab by David Simon indicating that all necessary apoptotic machinery is 
contained within the axon (see below). 
 






Figure 1.6 EGTA causes Caspase-3 activation in uncut axons. DRG explants 
were cultured for 2 days in vitro (DIV). Axons were either left intact or physically 
separated from their cell bodies by cutting (indicated by dashed red line). 
Explants were then treated with 2mM EGTA as indicated and Caspase-3 










Figure 1.7 Axotomy prevents Caspase-3 activation in axons after TD. Axons 
from 7DIV DRG explant cultures were severed from cell bodies by manual punch-
out of the center cell mass. Wallerian degeneration was prevented by addition of 
2mM EGTA and cultures were subject to TD by addition of NGF function-blocking 
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In thinking about what the critical factors in the cell body might be, I 
focused on a puzzling result that came out of the genetic screen I was 
conducting. As will be detailed below, despite significantly delaying axon 
degeneration after TD, Puma was only detectable within the cell body. Further, 
Caspase-3 activity appeared to radiate out from the cell body over a time course 
of TD as assayed by immunofluorescence for Fractin, an actin neoepitope 
formed by Caspase-3 cleavage (Sokolowski et al., 2014)(Fig 1.8). These insights 
fundamentally changed the direction of my thesis work leading to the 
identification of a cell body derived signaling program that controls axon 
degeneration after TD. The results, all of which were obtained in close 
collaboration with David Simon, are therefore presented in a format that follows 
the most cohesive narrative rather than reflecting the true chronology of how the 
project developed. 
In Chapter 2, I will discuss our finding that contrary to a prior study (Ghosh 
et al., 2011), the apoptotic machinery is present and functional in axons, but it is 
not activated directly by distal TD. Rather, the initiating signal for degeneration 
comes from the cell body, following activation by convergent retrograde signals 
(loss of Akt signaling and activation of JNK signaling) from the distally deprived 
axon. Further, we found that the transcription factors c-jun and Foxo3a are 
primary targets of these convergent retrograde signals. 
Chapter 3 will focus on a screen of pro-apoptotic Bcl-2 family members, 
which identified Puma as the key regulator of axon degeneration. We find that 
36 
Foxo3a dependent upregulation of Puma transcription is the key regulated step 
of this process and that Puma activity is tightly controlled by the anti-apoptotic 
Bcl-2 family members Bcl-w and Bcl-xL, themselves identified in a separate 
genetic screen. Although Puma potently protects distal axons from degeneration 
following TD, we find, quite unexpectedly, Puma expression is confined to the cell 
body. 
Chapter 4 explores results implying that rising Puma levels overcome 
inhibition by Bcl- xL and Bcl-w, then trigger axon degeneration by an additional 
somatically-derived factor(s), distinct from Puma, that moves from the cell body 
to the axon. I further discuss data indicating that this factor is partially JNK 
dependent and present p53 as a possible candidate. I conclude with a general 
discussion of the results and suggestions for future experiments that can build on 
this work. 







Figure 1.8 Caspase activity radiates from the cell body after TD. DRG 
explants cultured for 2 DIV were subjected to TD for the times indicated. 
Immunofluorescence was used to visualize Tuj1 and the Caspase-3 cleavage 
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Chapter 2: A transcriptional program in the cell body is 
required for the initiation of axon degeneration 
 
Rationale 
 The prevailing view in the field argues that distal axon degeneration is 
initiated and executed by a local mechanism contained within the axon itself 
(Ghosh et al., 2011). This model has been called into question by a recent study 
showing that axons severed from their cell bodies, but protected against injury-
induced Wallerian degeneration by genetic deletion of Sarm1, do not show 
cleaved Caspase-3 immunoreactivity after trophic factor withdrawal (Gerdts et al., 
2013). Further, inhibition of transcription and inhibition of GSK3β specifically in 
the cell body also prevent axon degeneration after TD, arguing against a 
degenerative mechanism contained exclusively within the axon (Chen et al., 
2012). We sought to conclusively determine if the cell body plays an active and 
essential role in axon degeneration and, if so, which signaling pathways were 
responsible for initiating and executing the degenerative process. 
 
Apoptotic machinery is present in axons but requires the cell body for 
activation by TD   
NGF-dependent sensory axons undergo Caspase-dependent 
degeneration when deprived of neurotrophic (NGF) support.  This degeneration 
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is seen both when the entire neuron is deprived and when the manipulation is 
restricted to the axon through use of compartmented Campenot chambers that 
allow for independent manipulation of axons and cell bodies via fluid isolation of 
these compartments (Campenot, 1977).   
To begin to explore the role of the cell body in regulating local 
degeneration, we severed axons from their cell bodies and subjected the isolated 
axons to TD.  To exclude confounding effects of degeneration induced by the 
injury (Wallerian degeneration), we performed these experiments using sensory 
neurons from a transgenic mouse expressing cytoplasmic NMNAT1, which 
protects axons from Wallerian degeneration (Vohra et al., 2010) but does not 
interfere with cleavage and enzymatic activity of Caspase-3 in response to TD in 
intact neurons (Figure 2.1).  Separation of axons from their cell bodies completely 
blocked appearance of cleaved Caspase-3 immunoreactivity 9 hrs following TD, 
in contrast with strong immunoreactivity in intact axons (Figure 2.2).  This result 
confirmed that the cell body is required for caspase-dependent degeneration in 










Figure 2.1 Cytoplasmic NMNAT1 protects axons downstream of Caspase-3 
activation. WT embryonic DRG cultures were transduced with lentivirus 
expressing cyto-NMNAT1 or GFP and grown for 12 days. Lysates were prepared 
at indicated time points after TD. Axon degeneration and the activation of 
Caspase-3 and downstream calpains was assayed by immunoblot.  
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Figure 2.2 Caspase-3 cleavage after TD requires the cell body, but 
Caspase-3 can be induced exogenously in isolated axons. Following 2 days 
in culture, a portion of the axons in explants from cytoNMNAT1-Tg mice were 
physically severed from their cell bodies (indicated with a dashed red line) 
followed immediately by TD (top row) or the addition of 10μM ABT-737 (bottom 
row) for the indicated times. See illustration. Cleaved Caspase-3 was visualized 
by immunostaining.  
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A possible explanation for cell body dependence would be if the cell body 
is continually required to replenish components of the apoptotic pathway. To test 
whether the apoptotic machinery is present and functional in axons that have 
been disconnected from their cell bodies, we exposed isolated axons to ABT-
737, a selective antagonist of the three pro-survival factors Bcl-2, Bcl-xL and Bcl-
w (Oltersdorf et al., 2005), which causes Bax- and Caspase-3-dependent axon 
degeneration when applied directly to axons in Campenot chambers, even in the 
presence of NGF (Simon et al., 2012).  We found that the response to ABT-737 
is also Caspase-9-dependent and can be blocked by Bcl-xL overexpression 
(Figure 2.3A, B), further indicating its specificity. 10 μM ABT-737 triggered robust 
Caspase-3 cleavage in isolated NMNAT1-Tg axons, as assessed by 
immunohistochemistry (Figure 2.2).  To quantify this effect, we lysed isolated 
NMNAT1-Tg axons in a buffer containing a luciferase based probe for Caspase-
3/7-like enzymatic activity (hereafter referred to as ‘DEVDase’ activity, as the 
Caspase target sequence in the probe is DEVD).  Consistent with the results of 
immunohistochemistry, application of 10 μM ABT-737 increased DEVDase 
activity in isolated axons but TD did not (Figure 2.4A).  TD also did not increase 
Caspase activity triggered by ABT-737 in these isolated axons, as assessed by 
measuring DEVDase activity (Figure 2.4A) and cleaved Caspase-3 
immunoreactivity (Figure 2.4B). 
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Figure 2.3 Genetic deletion of Caspase-9 or overexpression of Bcl-xL is 
protective against ABT-737. (A) Axon degeneration induced by ABT-737 is 
Caspase-9 dependent. 7DIV WT or Caspase-9 KO embryonic DRG explants 
were treated with 10μM ABT-737 for 12hr. Caspase-3 cleavage is visualized by 
immunostaining.   (B) Caspase-3 cleavage following ABT-737 application is 
blocked by Bcl-xL overexpression. Embryonic DRG cultures were transduced 
with lentivirus expressing Bcl-xL or GFP and treated with 10μM ABT-737 for 
12hr. Caspase-3 cleavage in axons was visualized with immunostaining.  
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Figure 2.4 Effect of TD on ABT-737 treatment in cut and uncut axons.  
(A and B) Isolated axons are not sensitized to ABT-737 treatment after TD. 
Axons from 2DIV cytoNMNAT1-Tg dissociated and reaggregated DRG explants 
were severed from their cell bodies (indicated with a dashed red line) and treated 
with ABT-737 for 4hr in the presence of NGF or following 2hr TD (for a total of 
6hr TD) as indicated. DEVDase activity in these isolated axons was subsequently 
measured by Caspase-Glo-3/7 assay (A) or Cleaved Caspase-3 was visualized 
by immunostaining (B). n=4 for all conditions except 1μM and 10μM ABT-737 
plus TD where n=3. Values are normalized to the average value of the +NGF 
control condition. Statistical significance for each 10μM dose is determined 
relative its respective Control condition.  
(C and D) TD sensitizes axons to ABT-737 treatment. Embryonic DRG cultures 
were treated with ABT-737 in the presence of NGF or following 2hr TD (for a total 
of 6hr) as indicated. Following treatment, either cell bodies were removed and 
axonal DEVDase activity was measured with the Caspase-Glo-3/7 reagent (C) or 
Cleaved Caspase-3 was visualized by immunostaining (D). n=4 for all conditions 
except 10μM ABT-737 plus TD where n=3. Values are normalized to the average 
value of the +NGF control condition. Values are presented as mean ± SEM; 
**p<.01; ***p<.001 by ANOVA with Bonferroni tests. 
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We also applied ABT-737 to intact neurons, and observed a similar degree 
of DEVDase activation at 6hrs in their axons (which were isolated for DEVDase 
measurement at that time) as we had seen in isolated axons that were treated 
with ABT-737 only after being severed from their cell bodies (compare Figure 
2.4A and C). Interestingly, in these intact neurons, a brief period of TD that was 
itself insufficient to cause a detectible increase in DEVDase activity dramatically 
potentiated the response of their axons to ABT-737 (Figure2.4 C,D).  Thus, TD 
triggers an early cell body-dependent increase in the pro-apoptotic state of 
axons. 
Collectively, our results indicate that axons contain all necessary apoptotic 
machinery required to initiate Caspase-3 activation, but local TD is incapable of 
activating this machinery directly in isolated axons.  Instead, the triggering of 
axonal apoptosis by local TD requires connection of the axon to its cell body and 
is presaged by an early increase in the sensitivity of the axon to direct activation 
of the apoptotic pathway.  However, these results still do not establish whether 
the cell body is simply required in a permissive way for the effects of TD, or 
whether the cell body is a more active participant. 
Akt signaling controls axon survival and requires the cell body 
To elucidate the role of the cell body, we set out to map the pathway of 
degeneration.  For this, we first examined how local removal of NGF initiates the 
degenerative response.  One possibility is that the process is initiated by loss of 
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pro-survival signaling mediated by the kinase activity of TrkA, the NGF receptor. 
It has, however, been proposed alternatively that TrkA is a “dependence 
receptor”, which, when unliganded, sends a proapoptotic signal that is 
independent of its kinase activity (Nikoletopoulou et al., 2010).  To distinguish 
these possibilities, we interfered specifically with kinase-dependent signaling 
using sensory neurons from the TrkA F592A knock-in mouse in which TrkA is 
engineered to be sensitive to acute inhibition of its kinase activity by the small 
molecule 1NMPP1, which does not inhibit wild-type kinases (Chen et al., 2005b).  
Application of 1NMPP1 specifically to axons induced axon degeneration (Figure 
2.5A), consistent with loss of kinase activity being the driver of degeneration, 
rather than gain of a proapoptotic kinase-independent signal.  
A major pro-survival pathway downstream of TrkA kinase is Akt signaling, 
so we next explored involvement of Akt in the degeneration induced by TrkA 
inhibition by 1NMPP1. The degeneration was blocked by lentiviral expression of 
a constitutively active, myristoylated form of Akt1 (myrAkt1) (Figure 2.5B). 
MyrAkt1 also potently protected axons from degeneration following TD (Figure 
2.5C,D). Phosphoinositide PIP3-dependent activation of Akt is antagonized by 
the tumor suppressor phosphatase and tensin homolog (PTEN), so genetic 
deletion of PTEN represents an alternative strategy to activate Akt signaling. 
Sensory neuron cultures were therefore established from a conditional mutant of 
PTEN and infected with lentivirus expressing either GFP or Cre recombinase. 
Deletion of PTEN similarly protected axons from degeneration induced by TD, 
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though the duration of protection was shorter than for myrAkt1 expression (Figure 
2.6A, B), presumably because it is less effective at activating downstream Akt 
signaling. 
That Akt signaling regulates axon survival downstream of TrkA suggested 
acute pharmacological inhibition of Akt as a useful tool to probe the role of the 
cell body during TD. Acute pharmacological inhibition of Akt in the axonal 
compartment of Campenot chambers using the selective pan-Akt inhibitor GDC-
0068 induces axon degeneration (Figure 2.6C).  Activation of axonal Caspase-3 
induced by Akt inhibition was eliminated in Caspase-9 knockout cultures, 
indicating a specific activation of the apoptotic pathway by this treatment (Figure 
2.6D).  Further mirroring the dependence on cell body seen with local TD (Figure 
2.2), we found axonal Caspase-3 activation by GDC-0068 was prevented by 
axotomy in cultures derived from the NMNAT1 transgenic or by co-incubation 
with the transcriptional inhibitor Actinomycin D (Figure 2.6E).  These results 
further support a requirement for ongoing somatic transcriptional activity in 
mediating axonal Caspase-3 activation. 
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Figure 2.5 Constitutive Akt signaling protects against TrkA inhibition and 
TD. (A) Local inhibition of TrkA signaling induces axon degeneration. WT or TrkA 
F592A knock-in DRG sensory neurons were cultured in Campenot chambers and 
the axonal compartment was treated with vehicle or 1μM 1NM-PP1 for 24hr. 
Degeneration was visualized by immunostaining for TuJ1.  
(B) Constitutive Akt1 signaling promotes axon survival after TrkA inhibition. TrkA 
F592A dissociated DRG cultures were transduced with lentivirus expressing 
myristoylated-Akt1, Bcl-xL, or GFP and treated with 1μM 1NM-PP1 for 24hr. 
Degeneration was visualized by immunostaining for TuJ1. Lentiviral Bcl-xL 
overexpression also provided similar axonal protection (data not shown).  
(C and D) Constitutive Akt1 signaling promotes axon survival after TD. 
Embryonic DRG cultures were transduced with lentivirus expressing 
myristoylated-Akt1 or GFP and subjected to TD after 7 days in culture. Axon 
degeneration was visualized by TuJ1 immunostaining (C) and quantified over 
time (D). n=3 for each condition. Values are presented as mean ± SEM; 
***p<.001 by ANOVA with Bonferroni tests. 
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Figure 2.6 Akt signaling regulates axon degeneration via the cell body  
(A and B) Conditional deletion of PTEN delays axon degeneration after TD. 
PTENloxP/loxP dissociated and reaggregated DRG cultures were transduced with 
lentivirus expressing CRE or GFP and axon degeneration following TD was 
visualized by TuJ1 immunostaining (A) and quantified over time (B). Values are 
presented as mean ± SEM. n=5 for Lenti::GFP conditions and n=6 for Lenti::Cre 
conditons except 25hr TD where n=7  
(C) Local AKT inhibition induces axon degeneration. WT embryonic DRGs were 
cultured in Campenot chambers and 10μM of the Akt inhibitor GDC-0068 or 
vehicle was added to the axonal compartment for 18hr. Axon degeneration was 
visualized with immunostaining for TuJ1 and cleaved Caspase-3.   
(D) Axon degeneration induced by Akt inhibition is Caspase-9 dependent. WT or 
Caspase-9 KO embryonic DRG explants were cultured for 7 days and treated 
with the indicated compounds for 12hr. Caspase-3 cleavage was visualized by 
immunostaining.  
(E) Axon degeneration following Akt inhibition requires transcription and 
communication with the cell body. Axons from cytoNMNAT1-Tg explant cultures 
were severed from their cell bodies (red line) or pre-treated with 3μg/ml 
Actinomycin D for 1hr prior to addition of 10μM GDC-0068 for 12hrs. Axon 
degeneration and cleavage of Caspase-3 were visualized by immunostaining.   




Pro-degenerative JNK signaling is activated by loss of Akt signaling and 
requires the cell body 
Previous studies have implicated the MAPKKK DLK as a JNK pathway 
activator in the regulation of axon degeneration in response to TD (Huntwork-
Rodriguez et al., 2013; Ghosh et al., 2011).  We therefore used the Akt inhibitor 
to examine a possible connection between loss of Akt signaling and the JNK 
pathway.  Degeneration caused by acute Akt inhibition was significantly blunted 
in cultures of neurons in which DLK was genetically deleted (Figure 2.7A, B), 
placing DLK activation downstream of TD-associated loss of Akt signaling. Akt 
can directly phosphorylate DLK and inhibit its kinase activity (Wu et al., 2015), 
suggesting that DLK activation in response to local TD may reflect a disinhibition 
by removal of Akt signaling, although this remains to be established in our 
system.  
Figure 2.7 Conditional deletion of DLK delays axon degeneration induced 
by Akt inhibition. DLKloxP/loxP DRG cultures were transduced with lentivirus 
expressing CRE or GFP and subjected to treatment with 10μM GDC-0068 for 
indicated time points. Axon degeneration was visualized by TuJ1 immunostaining 
(A) and quantified over time (B). For Lenti::GFP n=5 for 15hr, n=7 for 20hr, and 
n=4 for 25hr. For Lenti::Cre n=8 for all conditions. Representative images are 
presented in Figure S2E. Values are presented as mean ± SEM; ***p<.001 by 
ANOVA with Bonferroni tests. 
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It has been suggested that DLK directly promotes degeneration through 
local activation of the apoptotic pathway in axons (Ghosh et al., 2011).   We 
cultured wild-type sensory neurons in Campenot chambers and subjected their 
axons to TD in the presence of a small molecule JNK inhibitor in either the axonal 
or cell body compartment.  We found that axonal inhibition of JNK signaling 
provides modest protection of axons, consistent with previous findings (Chen et 
al., 2012; Ghosh et al., 2011), but also found that inhibition of JNK activity 
exclusively in the cell body compartment (which had not previously been tested) 
protected axons to a much greater degree (Figure 2.8A, B).  This result was 
surprising because a previous study discounted the JNK target c-Jun as a 
significant regulator of axon degeneration (as opposed to cell body degeneration) 
(Ghosh et al., 2011).  Here we revisited those findings and observed instead that, 
in addition to protecting against somatic activation of Caspase-3, genetic deletion 
of c-Jun also promotes significant axon survival in dissociated sensory neuron 
cultures and explant cultures (Figure 2.9A,B,D,E).  We believe the discrepancy in 
findings is likely due to inefficient excision of c-Jun in the prior study, which used 
a transgenic line in which Cre recombinase is driven by the Nestin promoter.  
Indeed, we found that lentiviral delivery of Cre to c-Jun conditional knockout 
cultures, as done here, provides a much more complete deletion of the mature c-
Jun protein (Figure 2.9C).  Thus, our results argue that activation of DLK 
regulates cell body JNK/c-Jun signaling that is essential for axon degeneration, 
but is not sufficient to directly activate degeneration locally in axons. 
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Figure 2.8 Axon degeneration after TD requires somatic JNK signaling. 
Sensory neurons were cultured in Campenot chambers where cell bodies and 
axons are separated by a grease barrier that allows for fluidic isolation (See 
illustration). Cultures were treated with 10uM JNK inhibitor VIII or vehicle in either 
or both the cell body and axonal compartments, followed by TD as indicated. 
Degeneration was visualized by immunostaining for Tuj1 (A) and quantified (B). 
n=4 for each condition. Values are presented as mean ± SEM; **p<.01; ***p<.001 
by ANOVA with Bonferroni tests. 
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Figure 2.9 The role of c-jun in axon degeneration. 
(A and B) Genetic deletion of c-Jun delays somatic caspase-3 activation and 
axon degeneration after TD. Dissociated embryonic c-JunloxP/loxP DRG cultures 
were transduced with lentivirus expressing Cre or GFP and subjected to TD as 
indicated. Somatic Caspase-3 activation was visualized by immunostaining for 
Tuj1 and cleaved Caspase-3 (A) and quantified as the average fraction of 
cleaved Caspase-3+/TuJ1+ cells across 3 non-overlapping fields in each well 
(B). n=4 for each condition.  
(C) Viral Cre expression is necessary for full excision of c-Jun in DRGs. c-
JunloxP/loxP; Nestin::Cre or c-JunloxP/loxP embryonic DRGs were grown as 
dissociated reaggregated cultures and transduced with lentivirus expressing Cre 
where indicated. Cultures were lysed at indicated times and c-Jun expression 
was assayed by immunoblot.  
(D and E) Conditional deletion of c-jun delays axon degeneration after TD. c-
junloxP/loxP dissociated and reaggregated DRG cultures were transduced with 
lentivirus expressing CRE or GFP and axon degeneration following TD was 
visualized by TuJ1 immunostaining (D) and quantified over time (E). Values are 
presented as mean ± SEM. n=4 for all conditions except for 25hr and 30hr TD 
where n=6. 




TD activates a Foxo3a-dependent pro-degenerative program 
The observations that axon degeneration requires somatic JNK/c-Jun 
activity (Figure 2.8A,B) and axon degeneration following Akt inhibition requires 
transcription (Figure 2.6E) point to a pro-degenerative role of the cell body.  We 
took a candidate approach and searched for transcription factors known to be 
downstream of Akt and JNK. Specifically, we focused on the transcription factor 
Foxo3a, whose pro-apoptotic activity is inhibited by Akt-mediated 
phosphorylation (Brunet et al., 1999).  Following TD, we observed concurrent 
decreases in phosphorylation of Akt and of Foxo3a (Figure 2.10), consistent with 
transcriptional activation of Foxo3a. Interestingly, in DLK knockout cultures the 
decreases in Akt phosphorylation and Foxo3a phosphorylation following TD 
occurred significantly more slowly, suggesting that DLK might participate in a 
feedback loop that enhances Akt inactivation following TD. Nuclear import to 
enable transcriptional activation normally follows de-phosphorylation of Foxo3a, 
and indeed we observed a nuclear migration of Foxo3a within several hours of 
TD (Figure 2.11A).  Importantly, shRNA-mediated knockdown of Foxo3a strongly 
protected axons from degeneration following TD (Figure 2.11B-D), thus 
identifying Foxo3a as a key regulator of axon degeneration. 
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Figure 2.10 Dephosphorylation of Akt and Foxo3a during TD is suppressed 
by conditional deletion of DLK. DLKloxP/loxP embryonic DRG cultures were 
transduced with lentivirus expressing CRE or GFP and lysed at indicated time 
points after TD. Phosphorylation of Akt and Foxo3a were assessed by 
immunoblot using phospho-specific antibodies. 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Figure 2.11 Foxo3a is a key regulator of axon degeneration after TD (A) TD 
induces nuclear import of Foxo3a. WT dissociated DRGs were cultured for 7DIV 
and subjected to TD for 9hr. Foxo3a localization was visualized by 
immunostaining for TuJ1 and Foxo3a.  (B) Knockdown of Foxo3a was confirmed 
by immunoblotting.   (C and D) Foxo3a knockdown protects against axon 
degeneration after TD. WT embryonic DRGs were grown as dissociated 
reaggregated cultures and subjected to lentiviral-shRNA knockdown of Foxo3a or 
Scrambled control. Axon degeneration after TD was visualized by 
immunostaining for TuJ1 (D) and quantified (C). Values are presented as mean ± 
SEM; *p<.05; ***p<.001 by ANOVA with Bonferroni tests. 
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Conclusions 
Here we demonstrate that although the apoptotic machinery is present in 
axons, it is not activated directly by TD and, instead, requires the cell body. Distal 
TD abrogates TrkA kinase signaling, resulting in concurrent loss of retrograde 
pro-survival Akt signaling and gain of retrograde pro-degenerative DLK signaling. 
This leads to the activation of two transcriptional programs in the cell body, 
JNK/c-jun and Foxo3a. Inhibition of JNK signaling specifically in the cell body 
compartment of Campenot chambers protects axons from degenerating after 
distal TD. Similarly, conditional deletion of c-jun or knockdown of Foxo3a 
significantly delays axon degeneration in explants. Taken together, we have 
definitively shown that the cell body is required for axon degeneration after TD 
and identified the central transcriptional pathways required to initiate the pro-
degenerative signal. 
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Chapter 3: The pro-apoptotic protein Puma functions in 
the cell body to regulate axon degeneration 
Rationale 
Having identified JNK/c-jun and Foxo3a as key mediators of axon 
degeneration, we sought to elucidate the pro-degenerative targets of these 
transcriptional programs. Bax is required for axon degeneration after TD 
(Nikolaev et al., 2009) and Bax activity is regulated by members of the Bcl-2 
family of proteins, several of which are regulated transcriptionally (Puthalakath 
and Strasser, 2002). As a result, we conducted a genetic screen to identify pro-
apoptotic Bcl-2 family members that play a role in distal axon degeneration after 
TD.
Pro-apoptotic Puma regulates axon degeneration 
Axon degeneration after TD is Bax dependent (Nikolaev et al., 2009), but 
a recent study showed that although Apaf1 was required for neuronal apoptosis 
after NGF withdrawal, it was not required for distal axon degeneration after local 
TD, implying that a non-canonical mitochondrial apoptotic program operates in 
axons independent of cell bodies (Cusack et al., 2013). However, we found that 
conditional deletion of Apaf1 in sensory neurons resulted in robust protection of 
axons after TD, disputing the earlier finding and establishing that the canonical 
mitochondrial apoptotic program is executed in degenerating axons (Figure 3.1). 
It is possible that this discrepancy results from the earlier study examining axon 
pruning in microfluidic chambers, where axons retract to the divider without signs 
of fragmentation, instead of in whole explant or Campenot cultures, although this 
62 
remains to be determined. Given this finding we reasoned that upstream 
processes may converge on the classical regulators of Bax activity, the pro-
apoptotic ‘BH3-only’ family of Bcl-2 proteins, which includes 7 members (Figure 
3.2A). We therefore examined the expression of the 7 pro-apoptotic Bcl-2 family 
members in axons, cell bodies, and whole DRGs. While Hrk, Bmf, and Noxa 
were unable to be detected with multiple antibodies, Bid, Bim, Puma, and Bad 
were found in cell bodies, but only Bid was expressed in axons (Figure 3.2B). 
Given that pro-apoptotic Bcl-2 family members are regulated by several 
transcriptional and post translational mechanisms (Puthalakath and Strasser, 
2002), we examined their expression in cell bodies and axons over a time course 
of TD (Figure 3.2C,D). Puma and Bim showed noticeable increases in the cell 
body while a Bid cleavage product, corresponding to the molecular weight of the 
more apoptotically active caspase cleavage product tBid (Gross et al., 1999), 
was seen at later time points (Figure 3.2C). Bid cleavage was also seen in 
axons, initially highlighting this as the primary target for a subsequent screen 
(Figure 3.2D). 
Based on the expression analysis, we screened a panel of knockout mice 
deficient in members of this family for axonal protection in sensory neuron 
explant cultures after TD.  Mice with a genetic deletion for Hrk were included, 
despite not seeing evidence of expression, due to the known role of Hrk in 
neuronal apoptosis after TD (Imaizumi et al., 2004). Axons were not protected in 
Bad or Hrk single mutants or in Bid;Bim double mutants (Figure 3.3A-D, data not 
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shown). Furthermore, shRNA-mediated knockdown of Noxa provided no obvious 
axonal protection (data not shown).  Notably however, we observed potent 
axonal protection after genetic deletion of Puma (Figure 3.4 A,B).  Loss of Puma 
also completely blocked the appearance of axonal cleaved Caspase-3 in 
response to acute Akt inhibition (Figure 3.4C).  We also cultured Puma knockout 
neurons in Campenot chambers and similarly observed potent axonal protection 
following TD in the axonal compartment (Figure 3.4D,E).  Near complete 
protection was seen at early time points in Puma knockout cultures (e.g. only 
10% of axons had degenerated by 60 hr after TD in Campenot chambers, Figure 
3.4D,E), indicating that Puma is a key regulator of degeneration.  It should be 
noted, however, that this protection is slightly less complete than seen in Bax and 
Caspase-3 and -9 knockout cultures (Nikolaev et al., 2009; Simon et al., 2012), 
with Puma knockout 2DIV cultures degenerating by 40hr after TD (Figure 3.4A 
right panel). This suggests the presence of an additional Bax-activating factor(s), 
which remains to be defined, that functions in parallel to Puma and provides the 
residual pro-apoptotic activity. 
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Figure 3.1 Conditional deletion of Apaf1 delays axon degeneration after TD. 
Apaf1loxP/loxP dissociated and reaggregated DRG cultures were transduced with 
lentivirus expressing CRE or GFP and axon degeneration following TD was 
visualized by TuJ1 immunostaining (A) and quantified over time (B). Values are 
presented as mean ± SEM. n=4 for all conditions. Values are presented as mean 
± SEM; ***p<.001 by ANOVA with Bonferroni tests. 
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Figure 3.2 Several members of the pro-apoptotic Bcl-2 family are 
expressed in DRGs. (A) The mitochondrial apoptotic pathway is regulated by 
pro- and anti-apoptotic members of the Bcl-2 family. The balance of these factors 
regulates Bax/Bak oligimerization and activation of downstream Caspases.  (B) 
Several anti-apoptotic Bcl-2 family members are expressed in DRGs. Separate 
cell body and axon preparations were harvested from WT embryonic DRG 
cultures for immunoblot analysis.  (C and D) Levels of pro-apoptotic Bcl-2 family 
members in cell bodies and axons after TD. WT DRGs cultured for 7DIV and 
subjected to TD for the indicated times. Separate cell body (C) and axon (D) 
preparations were made and analyzed by immunoblot. Arrow indicates cleaved 
Caspase-3 and arrowhead indicates cleaved Bid (tBid). 
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Figure 3.3 Bad KO and Bid;Bim dKO do not protect against axon 
degeneration after TD. Embryonic DRG cultures from the indicated genotypes 
were grown for 2 days and subjected to TD for indicated times. Axon 
degeneration was visualized by immunostaining for TuJ1(A and C) and quantified 
(B and D). Representative images shown. n=4 for Bad KO and WT. n=3 for 
Bid;Bim dKO and dHet. 
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Figure 3.4 Puma is required for caspase dependent axon degeneration.  
(A and B) Puma KO protects against axon degeneration in whole explant 
culture after TD. Embryonic DRG cultures from the indicated genotypes were 
grown for 2 days and subjected to TD for indicated times. Axon degeneration 
was visualized by immunostaining for TuJ1(A) and quantified (B). 
Representative images shown. n=4 KO and 7 WT for Puma.  
(C) Caspase-3 cleavage following Akt inhibition requires Puma. Puma WT or 
KO embryonic explants were cultured for 7 days and treated with 10μM of the 
Akt inhibitor GDC-0068 for 12hr. Caspase-3 cleavage was visualized by 
immunostaining.  
(D and E) Axon degeneration following TD requires Puma. Puma WT, Het, or 
KO embryonic DRGs were cultured in Campenot chambers and the axonal 
compartment was subject to TD for the indicated times. Degeneration was 
visualized by immunostaining for TuJ1 (D) and quantified (E). n=6 +NGF, n=6 
36hr TD, and n=5 60hr TD for WT. n=6 +NGF, n=6 36hr TD, and n=3 60hr TD 
for Het. n=8 TD, n=7 36hr TD, and n=3 60hr TD for KO.   




Puma is classically described as a transcriptionally regulated gene 
induced by cellular stress (Yu and Zhang, 2009).  Interestingly, we found that 
Puma is basally expressed in sensory neuron cultures in the presence of NGF, 
and its levels are potentiated in response to TD.  The rise is Puma is also 
accompanied by the de novo appearance of a second Puma band at a slightly 
lower molecular weight (Figure 3.5A), whose molecular identity and physiological 
significance remain to be determined.  The increase in Puma expression and 
appearance of the second band occurred to a similar extent in Caspase-9 
knockout cultures (Figure 3.5B), which are protected from degeneration (Simon 
et al., 2012), indicating that both the rise of overall Puma levels and the 
appearance of the second band are not simply a secondary consequence of the 
degenerative process. Pharmacological inhibition of JNK prevented this TD-
induced rise in Puma (Figure 3.5A), consistent with a known role of c-Jun in 
promoting Puma expression (Wong et al., 2005) and providing a mechanism for 
the somatic requirement for JNK signaling that we observed (Figure 2.8). Puma 
has also been identified as a transcriptional target of Foxo3a (You et al., 2006), 
and accordingly we found that shRNA-mediated knockdown of Foxo3a in sensory 
neurons largely blocked the rise in Puma levels that accompanies TD (Figure 
3.5C). Thus, activation Puma appears to be a point of convergent action of 
Akt/Foxo3a and Jnk/c-Jun signaling that is required for axon degeneration 
following distal TD. 
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Figure 3.5 Factors regulating Puma expression. (A) Puma expression after 
TD is regulated by JNK. WT embryonic DRG neurons were treated with 10μM 
JNK inhibitor VIII or vehicle and protein was harvested at indicated time points 
after TD. Puma expression was assayed by immunoblot.   
(B) Appearance of Puma doublet is not Caspase-9 dependent. 7 DIV Caspase-9 
KO DRG cultures were harvested after TD. Puma expression was assayed by 
immunoblot.    
(C) Foxo3a regulates Puma expression during TD. Dissociated and reaggregated 
cultures from WT embryonic DRG neurons were subjected to lentiviral-shRNA 
knockdown of Foxo3a or Scrambled control. Protein was harvested at indicated 
time points after TD. Puma expression was assayed by immunoblot. 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Puma functions in the cell body to promote axon degeneration 
Puma can directly regulate Bax/Caspase activation, and since Caspase 
activation is observed in axons and deletion of Puma protects axons in 
Campenot chambers, we expected Puma to be present in axons as well.  We 
were therefore very surprised not to detect any Puma protein in axons.  Sensory 
neuron cultures were subjected to a time course of TD followed by clear 
separation and specific lysis of axons and cell bodies using methods that we 
have previously established (Yang et al., 2013). TD was accompanied by a rise 
in Puma protein levels in cell bodies, but there was no detectible signal in axons 
as assessed by immunoblotting (Figure 3.6A).  To confirm this finding, we used 
mass spectrometry.  We identified a number of stable Puma peptides, and used 
these as a basis to specifically probe for Puma in extracts of axons and cell 
bodies before and during TD.  As an internal control for similar protein content 
between samples, we found that two separate proteins with similar mass to 
Puma (Capzb and 14-3-3G) are present at equivalent levels in cell body and 
axon samples (Figure 3.6B-D). Using this approach we confirmed the presence 
of Puma in the cell body, but again did not detect Puma in the axon under any 
condition (Figure 3.6B-D).  We cannot of course exclude the presence of very 
low, undetectable levels of Puma in axons, however such expression would not 
be physiologically relevant as the strong expression of the Puma antagonists Bcl-
xL and Bcl-w that we observe in axons (see below) would be expected to inhibit 
the activity of any Puma that is present. 
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Figure 3.6 Puma expression is confined to the cell body.  
(A) Puma is not detected in axons. Separate cell body and axonal preparations 
were collected from WT embryonic DRG cultures at indicated time points after TD 
and subjected to immunoblot analysis.  Arrow indicates cleaved Caspase-3. 
(B) Puma peptides are exclusively identified in the cell body. At 12DIV Large-
scale cultures made from WT embryonic DRGs were subjected to TD for 24hr. 
Separate cell body and axonal samples were collected and analyzed by tandem 
mass spectrometry. The number of peptide spectral matches are shown for each 
sample for either Bbc3 (Puma) or the loading control Capzb (capping protein 
actin filament z-line) and 14-3-3 protein gamma (1433G). Peptides corresponding 
to Puma were found only in cell body samples, while peptides corresponding to 
Capzb and 1433G were found in all samples. 
C) Identified peptides are mapped on to the sequence of Puma. Peptides
identified in triplicate are shown in red, those identified in the initial identification 
experiment are shown in green. 
( D) Annotated spectra for all 5 identified Puma peptides.  
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To explore the molecular basis of this somatic restriction we exposed 
sensory neuron cultures to either the transcriptional inhibitor Actinomycin D or the 
translation inhibitor cycloheximide. Caspase-9 knockout cultures were used to 
prevent an apoptotic response due to drug-induced cellular stress; as mentioned, 
Puma levels change to the same extent following TD in these cultures as in wild-
type cultures (Figure 3.5B). Interestingly, following 20hr of Actinomycin D or 5hr 
of cycloheximide treatment, Puma protein became undetectable (Figure 3.7A), 
suggesting that Puma has an extremely short half-life in healthy cells and is 
subject to an active gene expression program.  Puma levels are similarly 
sensitive to cycloheximide during TD (Figure 3.7B), indicating that de novo 
expression rather than stabilization of existing Puma protein underlies its rise 
during TD.  This rapid turnover might in principle contribute to Puma’s exclusion 
from sensory axons, though it is possible that there are active mechanisms that 
exclude it as well.  Importantly, the dependence of axon degeneration on Puma, 
together with the exclusion of Puma from the axon, imply the existence of a 
somatically-derived triggering factor distinct from Puma that moves to the axon 
after TD as a consequence of Puma’s somatic activity. 
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Figure 3.7 Critical role of transcription and translation in maintaining basal 
Puma levels. (A) Maintenance of basal Puma levels requires transcription and 
translation. Caspase-9 KO embryonic DRG cultures in the presence of NGF were 
treated with ActinomycinD or cycloheximide, harvested at the indicated time 
points, and subjected to immunoblot analysis.  
(B) TD does not maintain Puma levels in the absence of translation. WT 
embryonic DRG cultures were subjected to TD, cycloheximide treatment, or TD 
following 1hr cycloheximide pre-incubation as indicated. Puma levels were 
analyzed by immunoblot.  
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Bcl-xL and Bcl-w regulate the survival of sensory axons 
Puma’s proapototic activity is antagonized by its binding to each of the known 
five anti-apoptotic Bcl-2 family members, three of which are the targets of ABT-
737 (Figure 3.2A).  We therefore examined the expression of the five anti-
apoptotic factors in axons, cell bodies, and whole DRGs by immunoblotting 
(Figure 3.8A).  We were unable to detect A1 protein in either axons or cells 
bodies; each of the four additional family members, Bcl-2, Bcl-w, Bcl-xL, and Mcl-
1 were expressed in sensory cell bodies, but only Bcl-xL and Bcl-w were 
detected in axons (Figure 3.8A).  Similarly to our approach with the pro-apoptotic 
Bcl-2 family proteins, we sought to determine the effect of TD on the levels of 
anti-apoptotic members, revealing two notable findings. First, Bcl-w appears to 
increase in the DRG cell body after TD, possibly due to a cessation of NGF 
stimulation which a recent study observed to halt mRNA and protein movement 
to axons (Cosker et al., 2013) (Figure 3.8B). Secondly, although levels of Bcl-xL 
do not show a significant change in cell bodies or axons, a lower molecular 
weight band appears in both axons and cell bodies coincident with Caspase-3 
activation (Figure 3.8B,C). This band corresponds to the Bcl-xL Caspase-3 
cleavage product Bcl-xS, which actually acts as a potent pro-apoptotic protein in 
neurons (Ofengeim et al., 2012).  Further, Bcl-xL localization within axons 
appears to shift from a continuous distribution along the axon to a noticeably 
punctate appearance before signs of axon swelling and fragmentation after TD 
(Figure 3.8D). This highlighted Bcl-xL, which had not previously been examined 
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Figure 3.8 Localization and dynamics of anti-apoptotic Bcl-2 family 
members in DRGs.  
(A) Several anti-apoptotic Bcl-2 family members are expressed in DRGs. 
Separate cell body and axon preparations were harvested from WT embryonic 
DRG cultures for immunoblot analysis. 
(B and C) Levels of anti-apoptotic Bcl-2 family members in cell bodies and axons 
after TD. WT DRGs cultured for 7DIV and subjected to TD for the indicated times. 
Separate cell body (B) and axon (C) preparations were made and analyzed by 
immunoblot. Arrow indicates cleaved Caspase-3 and arrowhead indicates 
cleaved Bcl-xL (Bcl-xS).  
(D) Localization of Bcl-xL in axons changes after TD. 2DIV explants were subject 
to 9hr TD and Bcl-xL was visualized with immunostaining. 
(E) Puma shows increased binding to Bcl-xL after TD. 7DIV WT DRG explants 
were lysed after TD for indicated times. Lysated were precleared with Protein 
A/G beads and normalized to protein concentration using BCA. 
Immunoprecipitation performed with antibody to Bcl-xL or isotype control and 
analyzed by immunoblot. 
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outside of overexpression experiments in this context, as a compelling candidate 
to regulate Puma activity. This was supported by immunoprecipitation 
experiments showing increased Bcl-xL and Puma binding after TD (Figure 3.8E), 
possibly as a result of increasing Puma levels (Figure 3.6A). 
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We decided to focus our analysis on Bcl-xL and Bcl-w in light of the results 
above and for three additional reasons: they are the only ones detected in axons; 
Mcl-1 is not targeted by ABT-737; and the Bcl-2-specific inhibitor ABT-199 
(Souers et al., 2013) did not induce axon degeneration in our assays (data not 
shown). Loss of Bcl-w accelerated axon degeneration in response to TD in both 
whole sensory explant cultures and in Campenot chambers (Figure 3.9 A,B, 
3.10A,B), consistent with previous findings (Courchesne et al., 2011).   
Surprisingly, loss of Bcl-xL resulted in a comparable phenotype, suggesting a 
shared role in the regulation of axon survival (Figure 3.9A,B, 3.10A,B). As 
expected from these results, genetic loss of Bcl-xL similarly sensitized axons to 
Akt inhibition (Figure 3.10C), as did genetic loss of Bcl-w (data not shown). 
Thus, Bcl-xL and Bcl-w each individually antagonize proapoptotic signaling that 
drives induced axon degeneration. 
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Figure 3.9 Genetic deletion of Bcl-w or Bcl-xL enhances axon degeneration 
in explant cultures after TD. Embryonic DRG cultures from the indicated 
genotypes were subjected to TD. Cultures were visualized by immunostaining for 
TuJ1 (A) and quantified (B). n=3 Bcl-xLloxP/loxP; Nestin::Cre and 4 for Bcl-xL+/+ Cre 
positive and Cre negative embryos. n=3 WT and 4 KO embryos for Bcl-w. Values 
are presented as mean ± SEM; *p<.05; **p<.01; ***p<.001 by ANOVA with 
Bonferroni tests.  
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Figure 3.10 Bcl-xL and Bcl-w regulate axon survival. 
(A and B) Axon degeneration following TD is accelerated by genetic deletion of 
Bcl-xL or Bcl-w. Embryonic DRGs from the indicated genotypes were cultured in 
Campenot chambers and the axonal compartment was subjected to TD for the 
indicated time points. Axon degeneration was visualized by TuJ1 immunostaining 
(A) and quantified (B). n=3 +NGF, n=3 24hr TD, and n=3 36hr TD for Bcl-
xLloxP/loxP. n=6 +NGF, n=5 24hr TD, and n=6 36hr TD for Bcl-xLloxP/loxP; 
Nestin::Cre. n=9 +NGF, n=8 24hr TD, and n=9 36hr TD for Bcl-w WT. n=9 +NGF, 
n=8 24hr TD, and n=9 36hr TD for Bcl-w WT. n=6 for all time points for Bcl-w KO. 
(C) Conditional deletion of Bcl-xL sensitizes axons to Akt inhibition. 7 DIV 
Embryonic DRG cultures from Bcl-xLloxP/loxP and Bcl-xLloxP/loxP; Nestin::Cre 
embryos were treated with the indicated concentrations of Akt inhibitor for 12hr. 
Caspase-3 cleavage was visualized by immunostaining. Values are presented as 
mean ± SEM; *p<.05; **p<.01; ***p<.001 by ANOVA with Bonferroni tests.  
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We next examined the effect of removing both Bcl-xL and Bcl-w.  
Strikingly, combined genetic deletion of the two caused gradual axon 
degeneration even in the presence of NGF (Figure 3.11), such that after 7 days 
in culture axons no longer survive.  What causes this degeneration?  The basal 
expression of Puma in sensory neurons in the presence of NGF distinguishes 
these neurons from many other cell types where Puma is absent until it is 
induced by cellular stress (Yu and Zhang, 2009).  We therefore tested whether 
Puma was responsible for the degeneration.  Consistent with this possibility, we 
found that the progressive degeneration observed in the presence of NGF 
following combined loss of Bcl-xL and Bcl-w is suppressed by further genetic 
deletion of Puma (Figure 3.12) (in this experiment, Puma and Bcl-w were deleted 
genetically, and Bcl-xL was knocked down by shRNA, because of the difficulty of 
obtaining triple knockout mice).  That Puma is epistatic to Bcl-xL and Bcl-w in the 
presence of NGF indicates both that basally expressed Puma is functional, and 
that a physiological role of the anti-apoptotic proteins in this context is to 
suppress basal Puma activity.  This finding also supports a role for Puma as an 
apoptotic activator even in the presence of NGF (albeit one that is normally 
inhibited by Bcl-xL/w). 
Finally, we examined the effect of TD on neurons with combined loss of 
Bcl-xL, Bcl-w and Puma (we could not study the effect of TD on Bcl-xL;Bcl-w 
double knockouts because they degenerated spontaneously: Figure 3.11). 
Interestingly, degeneration was still observed after TD (Figure 3.12). A likely 
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possibility is that this residual degeneration reflects the action of the parallel Bax-
activating factor that provides residual pro-degenerative activity in the absence of 
Puma (see above), and which we therefore infer is also inhibited by Bcl-w and 
Bcl-xL (since it is revealed in their absence). 
Figure 3.11 Combined deletion of Bcl-w and Bcl-xL initiates axon 
degeneration in the presence of NGF. Embryonic DRGs from indicated 
genotypes were grown as dissociated reaggregated cultures and transduced with 
lentivirus expressing CRE or GFP. Axon degeneration was visualized by 
immunostaining for TuJ1 at 3, 5, and 7 days post- infection.  
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Figure 3.12 Combined elimination of Bcl-w and Bcl-xL is epistatic to Puma 
deletion after TD. Puma KO or Puma KO; Bcl-w KO dissociated reaggregated 
DRG cultures were subjected to lentiviral-shRNA knockdown of Bcl-xL or 
Scrambled control. Following TD, axon degeneration was visualized by 
immunostaining for TuJ1 (A) and quantified (B). n=2 for all Puma KO conditions 
and n=4 for all Puma KO; Bcl-w KO conditions.  
Values are presented as mean ± SEM; ***p<.001 by ANOVA with Bonferroni 
tests.  
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Conclusions 
 Here we identify the pro-apoptotic Bcl-2 family member Puma as the 
central mediator of axon degeneration after TD. Foxo3a and JNK/c-jun 
dependent upregulation of this protein is the key regulated step of this process. 
Surprisingly, Puma is localized exclusively to the cell body where its pro-
degenerative capacity is inhibited by the anti-apoptotic Bcl-2 proteins Bcl-xL and 
Bcl-w, themselves expressed in both the cell body and axon. The somatic 
restriction of Puma, combined with the fact that axons with combined loss of Bcl-
xL, Bcl-w and Puma still degenerate after TD, implies the existence of an 
additional somatically derived pro-degenerative factor, distinct from Puma, that 










Chapter 4: A somatically-derived pro-degenerative 
signal initiates caspase-dependent axon degeneration 
Puma activates a somatically-derived pro-degenerative signal 
The picture that emerges from these studies is that basal Puma activity in 
the cell body is antagonized by Bcl-xL and Bcl-w, and that TD leads to a rise in 
Puma (and appearance of a second band) that overcomes this inhibition to 
activate an anterograde pro-degenerative signal that travels down the axon.   We 
argued above that this signal was not likely to be Puma itself because it is not 
detectable in axons (Figure 3.6A,B).  Several additional lines of evidence 
reinforced this conclusion. 
First, axons express abundant Bcl-xL and Bcl-w that could inhibit any low 
levels of Puma that might be present (Figure 3.8A), and although this expression 
declined after TD, the decrease was very modest, an effect that was not altered 
by Puma deletion (Figure 4.1), so that even after TD both remain abundant and 
presumably able to block any low level of Puma in axons. (Note: The decline in 
Bcl-xL in the cell body observed here is larger than that seen in Figure 3.8B 
possibly because dissociated and reaggregated cultures allow better elimination 
of support cells which can act as a confounding factor.) Second, we used ABT-
737 as a probe of the balance of pro- and anti-apoptotic Bcl-2 family members in 
the axon.  In these experiments, we monitored short-term responses to ABT-737 
(applied for 4 hrs).  If Bcl-xL and Bcl-w function to inhibit the apoptotic pathway 
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within axons, we would predict that genetic deletion of either factor should 
sensitize the axons to activation of this pathway by ABT-737.  Likewise, if Puma 
functions to promote the apoptotic pathway within axons, we would predict that 
loss of Puma would make the axons less sensitive to ABT-737.  We found that 
axons lacking either Bcl-xL or Bcl-w were indeed more sensitive to Caspase 
activation by ABT-737 across a range of doses, as assessed by DEVDase 
activity, whereas deletion of Puma did not alter axonal sensitivity (Figure 4.2A). 
Accordingly, axons lacking Bcl-xL or Bcl-w displayed earlier Caspase activation 
in response to a single dose of ABT-737, whereas those lacking Puma did not 
display a delay (Figure 4.2B,C). These results thus support a direct role for Bcl-
xL and Bcl-w within axons, but also support a lack of direct role for Puma in 
axons. 
Figure 4.1 Behavior of Bcl-xL and Bcl-w proteins in Puma KO. Puma WT and 
KO DRGs were grown as dissociated and reaggregated cultures for 7 days and 
subjected to TD for the indicated times. Axons and cell bodies were harvested 
independently and the behavior of Bcl-w and Bcl-xL proteins were analyzed by 
immunoblot.  
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Figure 4.2 Bcl-2 family members affect axonal response to ABT-737.  
(A) Genetic deletion of Bcl-xL or Bcl-w enhances caspase-like activity in axons 
treated with ABT-737, but deletion of Puma does not. Embryonic DRGs cultures 
from the indicated genotypes were treated with a range of ABT-737 
concentrations. Cell bodies were removed at the end of the treatment and axonal 
DEVDase activity was measured using the Caspase-Glo-3/7 assay. n=4 for all 
conditions except 10μM in Bcl-xL WT, 3μM in Bcl-xL KO, and 10μM in Bcl-w WT 
where n=3. Values are normalized to the average value of the control condition 
for each respective genotype. (B) Genetic deletion of Bcl-w accelerates Caspase 
activation after ABT-737 application. Bcl-w KO DRG cultures in the presence of 
NGF were treated with 10μM ABT-737 for the times indicated and Caspase-3 
activation was visualized by immunofluorescence. (C) Puma does affect Caspase 
activation after ABT-737 application. Puma KO DRG cultures in the presence of 
NGF were treated with 10μM ABT-737 for the times indicated and Caspase-3 
activation was visualized by immunofluorescence. Values are presented as mean 
± SEM; *p<.05; **p<.01 by ANOVA with Bonferroni tests.  
89 
Next, we returned to potentiation of the axonal response to ABT-737 by 
short-term TD (Figure 2.4C,D).  Since this potentiation is dependent on the cell 
body, we predict that it should require Puma activity.  Indeed, genetic deletion of 
Puma abolished the potentiating effect of TD on the axonal response to ABT-737 
(Figure 4.3).  This finding reinforces that Puma is capable of regulating axonal 
sensitivity but appears to do so at the level of the cell body. 
Collectively, these results further support the view that Puma functions in 
the cell body to activate an anterograde pro-degenerative signal that is distinct 
from Puma itself (Figure 4.4). 
Figure 4.3 Axonal sensitization to ABT-737 after TD requires Puma. 
Embryonic DRGs cultured from Puma WT and KO embryos were treated with 
ABT-737 for 4hr in the following 2hr TD (for a total of 6hr TD) as indicated. 
Following treatment, either cell bodies were removed and axonal DEVDase 
activity was measured with the Caspase-Glo- 3/7 reagent (A) or Caspase-3 
activation was visualized by immunostaining (B). n=4. Values are normalized to 
the average value of the control condition for each respective genotype.  
Values are presented as mean ± SEM; ***p<.001 by ANOVA with Bonferroni 
tests. 
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Figure 4.4 Model for the role of the cell body in the initiation of axon 
degeneration.  
The somatically-derived pro-degenerative signal is JNK dependent 
To gain mechanistic insight into the nature of the the somatically derived 
pro-degenerative signal we returned to the result that axons with combined loss 
of Bcl-w, Bcl-xL, and Puma are healthy in the presence of NGF but still 
degenerate after TD (Figure 3.12). As mentioned above, this supports a model 
whereby an additional pro-degenerative factor, normally regulated by Bcl-xL and 
Bcl-w and de-repressed by Puma, is activated by TD. Since JNK signaling is 
critical to Puma upregulation seen after TD (Figure 3.5A), we sought to examine 
if the additional pro-degenerative is dependent on this pathway. Pharmacological 
inhibition of the JNK suppressed the degeneration observed (Figure 4.5A.B), 
suggesting that indeed, the JNK signaling pathway regulates the activity of this 
pro-degenerative triggering factor. This further fills in the emerging picture of the 
molecular pathway involved in regulating axon degeneration (Figure 4.5C). 
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Figure 4.5 Activity of the anterograde pro-degenerative signal is regulated 
by JNK.  
(A and B)Puma-/-; Bcl-w+/- embryonic DRG dissociated reaggregated cultures 
were subjected to lentiviral-shRNA knockdown of Bcl-xL or Scrambled control. 
Cultures were then subjected to TFD in the presence of 10μM JNK inhibitor VIII 
or DMSO control. Axon degeneration was visualized by immunostaining for TuJ1 
(A) and quantified (B).. n=4 for all conditions.  
(C) Model of the molecular pathway involved in axon degeneration after TD. In 
the presence of NGF, Akt inhibits Foxo3a and JNK/c-jun activity, which keeps 
Puma levels low and ensures that Bcl-xL and Bcl-w can inhibit Bax and prevent 
degeneration. After TD, Akt inhibition of Foxo3a and JNK/c-jun is abolished, 
leading to increased Puma levels that inhibit Bcl-xL and Bcl-w in the cell body 
while also potentially activating Bax. Simultaneously, JNK signaling regulates the 
activity of the anterograde signal, which initiates axon degeneration in a Puma 
dependent manner. 
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P53 regulates axon degeneration independent of Puma transcription 
Expression of several critical mediators of the mitochondrial apoptotic 
program are regulated by the transcription factor p53, including Bax, Apaf1, and 
Puma (Beckerman and Prives, 2010). Given this, we sought to determine the 
function of p53 in axon degeneration after TD and found that deletion of this gene 
delayed axon degeneration both in whole explant culture and after TD of distal 
axons in Campenot chambers (Figure 4.6A, B). Surprisingly, this robust 
protection was not due to reducing Puma expression after TD, as both WT and 
KO cultures showed similar expression (Figure 4.6C). Bax can also be directly 
activated by p53, acting in a non-transcriptional role highly reminiscent of pro-
apoptotic Bcl-2 family members (Chipuk et al., 2004). Of note, the pro-apoptotic 
function of p53 in this context is known to be tightly regulated by Bcl-xL binding, 
which itself can be disrupted by Puma (Chipuk et al., 2005; Follis et al., 2013; Xu 
et al., 2006). As both Puma and Bcl-xL are essential components of the pathway 
outlined in this study, we reason that the protection observed by genetic deletion 
of p53 may be due to its non-transcriptional role and, further, it may in fact be the 
anterograde pro-degenerative factor described above. In accordance with this, 
p53 KO explants did not show a noticeable reduction is Caspase-3 activation in 
cell bodies after TD but did show a striking reduction in axonal Caspase-3 activity 
and Bid cleavage (Figure 4.6C,D). We cannot completely rule out a 
transcriptional role for p53 in this process, however the phenotype observed is 
unlikely to be a result of decreased Bax expression because axons of DRG 
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Figure 4.6 Genetic deletion of p53 protects axons after TD 
(A) p53 KO protects against axon degeneration in whole explant culture after TD. 
Embryonic DRG cultures from the indicated genotypes were grown for 2 days 
and subjected to TD for indicated times. Axon degeneration was visualized by 
immunostaining for TuJ1.  
(B) Axon degeneration following TD requires Puma. P53 WT or KO embryonic 
DRGs were cultured in Campenot chambers and the axonal compartment was 
subject to TD for the indicated times. Degeneration was visualized by 
immunostaining for TuJ1. 
(C and D) p53 KO reduces Caspase-3 activation in axons after TD, but does not 
affect Puma expression. p53 WT and KO DRGs were grown as dissociated and 
reaggregated cultures for 7 days and subjected to TD for the indicated times. cell 
Cell bodies (C) and Axons (D) were harvested independently and analyzed by 
immunoblot.  
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explant cultures heterozygous for Bax are not protected from TD (data not 
shown), but the effect may still be caused by reduced expression of other pro-
apoptotic proteins such as Apaf1. Nonetheless this result does position p53 as a 
compelling candidate for the as yet unidentified factor downstream of Puma. 
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Conclusions 
We demonstrate that rising Puma levels in response to TD overcome 
inhibition from Bcl-xL and Bcl-w to activate an anterograde pro-degenerative 
signal that travels down the axon. Genetic deletion of Puma does not make 
axons less sensitive to ABT-737, further arguing against it having a direct pro-
apoptotic role within the axon. However, Puma is required for the potentiation of 
axonal ABT-737 response that results from short-term TD, demonstrating a role 
for Puma in regulating axonal sensitivity at the level of the cell body. The 
additional anterograde factor implied by these results is partially JNK dependent. 
We show that p53 regulates TD induced distal axon degeneration, but not by 
reducing Puma expression. As p53 is known to have a non-transcriptional role as 
a direct Bax activator and genetic deletion of p53 appears to reduce TD-induced 
Caspase-3 activation specifically in the axon, it represents a promising candidate 
for the additional factor.
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Chapter 5: Discussion and Future Directions 
A prevailing view in the field has been that axon degeneration is a local 
event confined to the specific axon that loses neurotrophic support (Luo and 
O'Leary, 2005; Neukomm et al., 2014; Pease and Segal, 2014; Schuldiner and 
Yaron, 2015). This view is supported indirectly by observations in the clinical 
literature that axon degeneration precedes overt cell loss in a range of 
neurodegenerative conditions. Here we challenge this view and show that, during 
developmental sensory axon death in response to distal trophic deprivation, 
signaling via the cell body is an integral component of the molecular pathway that 
initiates axon degeneration. We show that the apoptotic machinery is present in 
the axon but that its activity is gated by an active process in the cell body which 
can be broken down into three discrete steps following distal TD: (1) retrograde 
signaling to the cell body (2) the key regulated step of Foxo3a-mediated 
upregulation of Puma in the cell body, enabling it to overcome inhibition by Bcl-xL 
and Bcl-w, and initiate the degenerative program, and (3) the ultimate triggering 
of axon degeneration by an as yet unidentified somatically-derived factor distinct 
from Puma that moves down the axon (Figure 4.4). By integrating distinct 
signaling pathways that originate within the axon, the cell body functions as a key 
check-point to initiate axon degeneration. 
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Retrograde signaling converges to increase Puma expression 
In chapter 2, we first confirmed previous studies by showing that in axons 
separated from their cell bodies, TD cannot induce Caspase-3 activation (Gerdts 
et al., 2013). However, through use of the Bcl-2 antagonist ABT-737, we 
established that axons do in fact contain a full complement of the apoptotic 
machinery, as it can be activated exogenously. Furthermore, TD can potentiate 
the effect of Bcl-2 inhibition, but only in axons retaining their cell body connection, 
positioning the cell body as a key regulator of the axonal apoptotic pathway. 
The cessation of TrkA kinase activity after TD results in a retrograde pro-
degenerative signal communicated to the cell body that is coordinated by loss of 
axonal Akt signaling. Constitutive activation of Akt1 or deletion of its negative 
regulator PTEN strongly protect axons from TD-induced degeneration. Akt is a 
multifunctional kinase with a number of well-documented roles in the survival and 
proliferation of various tissues. This study demonstrates that it suppresses the 
activity of two central pro-degenerative signaling pathways; namely the 
DLK/JNK/c-Jun pathway and the Foxo3a-dependent transcriptional program 
which, as we show in chapter 3, upregulates pro-apoptotic Puma expression. 
Loss of Akt signaling activates the DLK/JNK/c-Jun pathway culminating in 
pro-apoptotic MAPK signaling and activation of c-Jun. Interestingly, the loss of 
Akt activity after TD is slowed in the DLK knockout, suggesting a feedback loop 
back from DLK to Akt that accelerates inactivation of Akt in wild-type axons 
(Figure 2.10). A similar feedback loop exists in neuronal apoptosis induced by 
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arsenite (Wong et al., 2005) suggesting this could be a general phenomenon. 
Whether DLK inhibition and Akt are directly linked is unknown, but DLK does 
contain a number of Akt consensus sites that are inhibitory (Wu et al. 2015). 
Future studies aimed at introducing DLK mutations into those sites could 
establish direct phosphorylation of DLK by Akt as a central regulatory node in 
axon degeneration. 
As mentioned above, the previous view in the field was that local JNK 
signaling, independent of the cell body, was responsible for initiating TD-induced 
axon degeneration. This model was supported by a result showing that genetic 
deletion of c-Jun in neurons protected cell bodies but not axons (Ghosh et al., 
2011). We demonstrate that finding is incorrect, as more efficient excision of c-
Jun in fact protects both axons and cell bodies. Further, specifically inhibiting 
JNK in the cell body provides even more robust protection against TD-induced 
degeneration than axonal JNK inhibition (Fig 2.8). Thus, we prove that pro-
degenerative DLK/JNK signaling functions as a retrograde signal to the cell body 
with the ultimate role of activating the c-Jun transcriptional pathway. The genes 
that are regulated by this process remain to be elucidated although there is 
reason to believe Puma is one of the primary targets, as c-Jun is a known Puma 
transcriptional activator (Zhao et al., 2012). JNK/c-Jun dependent regulation of 
Puma has also been demonstrated in models of apoptosis after potassium 
withdrawal of cerbebellar granule neurons or β-amyloid treatment of cortical 
neurons (Akhter et al., 2015; Ambacher et al., 2012). Although we do show JNK 
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inhibition decreases the Puma response after TD (Fig 3.5A), future experiments 
examining this in c-Jun mutant neurons are necessary. In addition, although we 
demonstrate that the previous cell body independent model is incorrect, we have 
not completely ruled out a role for local JNK signaling in the axon. Indeed, axonal 
JNK inhibition provides a modest axonal protection (Fig 2.8), but whether this is 
because it interferes with the retrograde signal moving back to the cell body or 
because it suppresses a local pro-degenerative signaling program in the axon 
remains to be determined.  
The second function of Akt signaling is to suppress Foxo3a-dependent 
Puma upregulation. We show that Foxo3a is dephosphorylated upon distal TD 
and migrates to the nucleus where it is required to increase Puma expression 
(Figure 2.10, 2.11, 3.5C). A similar role for Akt/Foxo3a pathways in Puma 
induction has been described in the context of apoptotic cell body death of 
cerebellar granule neurons deprived of extracellular potassium (Ambacher et al., 
2012). Interestingly, somatic GSK3β, a known Akt target (Cross et al., 1995), has 
also been implicated in promoting Puma expression in cerebellar neurons 
(Ambacher et al., 2012) and in sensory axon degeneration following TD (Wu et 
al., 2015), so it might contribute to the Puma induction we describe here. Future 
experiments could fully examine the role of these pathways by combining 
deletion/chemical inhibition of all three pathways and determining if this fully 
abolishes Puma expression in this system. 
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Puma drives a pro-degenerative cascade in the cell body 
In chapter 3 we show that upregulation of Puma defines the key regulated 
step in the initiation of axon degeneration. Genetic deletion of Puma potently 
protects axons after TD (Figure 3.4) highlighting its central function in the 
degenerative cascade. Surprisingly, Puma is expressed in healthy neurons even 
in the presence of trophic support (Figure 3.5A) (unlike in many other cell types 
where it is absent until induced by stress), but its pro-degenerative activity is 
blocked by pro-survival Bcl-xL and Bcl-w. The most notable characteristic of the 
rise in Puma after TD is the appearance of a second lower-molecular weight 
band, whose identity is currently unknown. A Puma doublet is not observed in the 
vast majority of studies, but it is upregulated in sympathetic neurons after DNA 
damage (Wyttenbach and Tolkovsky, 2006), suggesting it could potentially be a 
neuronal specific isoform. To gain insight into this peptide, RNAseq could be 
utilized to identify unique Puma transcripts that increase after TD with a predicted 
lower molecular weight. Once identified, this Puma transcript could be cloned to 
examine its Bcl-xL and Bcl-w binding affinity relative to that of the heavier Puma 
isoform.  Further, its ability to induce Bax activation could be tested using in vitro 
mitochondrial permeabilization assays as has been done in other systems 
(Cartron et al., 2004; Letai et al., 2002). 
Puma is known to be post-translationally regulated by phosphorylation of 
serine-10. This event reduces Puma stability and Puma containing a serine to 
alanine mutation in this residue has increased apoptotic potential (Fricker et al., 
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2010). We show that only the upper Puma band is expressed in DRGs in the 
presence of NGF, which would fit with it being phosphorylated. Further, the short 
half-life of Puma in DRGs (Figure 3.7), makes the regulation of its stability by 
phosphorylation an intriguing possibility. Treatment of sensory neurons lysates 
with phosphatase could determine if the upper Puma band is this unstable, 
phosphorylated form, as western blots would show the distinct upper and lower 
bands collapsing to one lower band. In this scenario, studies uncovering the 
kinase responsible for the phosphorylation and how this leads to inhibition could 
uncover another striking level of regulation in this process. 
The identity of the anterograde pro-degenerative factor 
Following TD, the rise in Puma levels overcomes the inhibition of Bcl-w 
and Bcl-xL, leading to the activation of an anterograde pro-degenerative signal 
that travels down the axon. Our results imply that this signal is distinct from Puma 
itself, as Puma is only detectable in the cell body, even after TD, as assessed 
using two independent techniques (Figure 3.6). While it remains possible that a 
small amount of Puma (below the threshold of detection) is present in axons, it 
would be neutralized by the abundant Bcl-xL and Bcl-w present there, so any 
Puma within axons is unlikely to account for the large degenerative phenotypes 
documented here. The identity of the anterograde pro-degenerative signal 
remains to be determined. Our results also imply that to activate the Caspase 
pathway this signal must overcome the antagonistic effects of Bcl-xL and Bcl-w 
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within the axons. Further, its activity is regulated by JNK signaling, showing that it 
shares a common molecular pathway with TD-induced Puma expression. 
In thinking of the nature of this factor, several distinct possibilities exist, 
which are outlined below: 
Model 1: Activated Caspase-3 is the triggering factor 
 The first possibility is that the anterograde triggering factor is activated 
Caspase-3 itself, normally produced by somatic activation of the mitochondrial 
apoptotic pathway in a Puma dependent manner. In support of this, Caspase-3 
activation in the cell body precedes axonal Caspase-3 activation in explants 
subjected to TD (Figure 3.6). Caspases are increasingly recognized for their non-
apoptotic roles in shaping cell physiology and morphology (Hyman and Yuan, 
2012; Kuranaga and Miura, 2007), suggesting that sub-apoptotic Caspase-3 
activity may be able to induce neuronal pruning. This model requires the 
existence of an additional pro-apoptotic factor operating in the cell body in a 
redundant manner to Puma, because genetic deletion of Puma does not provide 
equivalent protection to Bax knockouts and neurons lacking Puma, Bcl-w, and 
Bcl-xL still degenerate after TD (Figure 3.12). It is possible that the Puma-
redundant factor is one of the other pro-apoptotic Bcl-2 family members that is 
expressed in the cell body (i.e. Bim or Bid), possibly kept in check by Mcl-1 or 
Bcl-2. Lentiviral knockdown of these additional pro-apoptotic Bcl-2 family 
members on top of cultures depleted of Puma, Bcl-w, and Bcl-xL could serve to 
identify this factor. 
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To test whether Caspase-3 is the triggering factor, two crucial experiments 
could be performed. The first would be to examine if low-level Caspase-3 activity 
is observed in the cell bodies of neurons whose distal axons are subjected to TD 
in Campenot chambers, instead of depriving whole explants, which also results in 
apoptosis. Although studies have claimed that an increase in cell death is not 
seen after distal axon deprivation (Campenot, 1982; Campenot et al., 1991; Mok 
et al., 2009), Caspase-3 activity has never been assessed. Because only a 
minority of the neurons plated in the center cell body compartment will be 
connected to axons that successfully cross the grease barrier into the axonal 
compartment, Alexafluor conjugated Cholera toxin subunit B (CTB) could be 
added to the axon compartment to retrogradely label the cell bodies connected to 
those axons. Axons could then be subjected to distal TD and Caspase-3 
activation in the CTB labeled cell bodies could be assessed by 
immunofluorescence. Increased cleaved Caspase-3 immunoreactivity would 
support a model whereby Caspase activity originating in the cell body flows out to 
the axon, resulting in degeneration. Nuclear morphology of these neurons could 
also be assessed to ensure that axon degeneration in this context is not merely a 
consequence of somatic death. 
Caspase-3 activity appears to radiate out from cell bodies in explants 
subject to TD (Figure 1.8), but to truly argue that this represents the movement of 
active Caspase-3, one would need to exclusively track the movement of cleaved 
Caspase-3 and not the zymogen. In an ideal scenario, a photoconvertible 
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fluorescent tag such as mEOS (McKinney et al., 2009) could be attached 
specifically to cleaved Caspase-3. The tag could be activated in cell bodies of 
neurons in Campenot chambers subject to axonal TD and one could use live 
imaging to determine if the radial pattern of Caspase-3 activity is the result of 
movement of cleaved Caspase-3 from the cell body to the axon. However, this 
method cannot be used because there is currently no way to tag cleaved 
Caspase-3 without tagging the zymogen as well, making it impossible to 
conclude that movement of the fluorescent tag truly represents the movement of 
proteolytically active Caspase-3. A similar issue would plague the use of 
fluorescent reporters used for live imaging of Caspase-3 activity (Bardet et al., 
2008; Zhang et al., 2013). In this case, live imaging of DRGs in Campenot 
chamber subject to axonal TD may reveal Caspase activity, as assessed by 
Caspase induced fluorescence, moving from the cell body distally down the axon. 
However, whether this represents the movement of proteolytically active 
Caspase-3 or some other factor that is inducing Caspase-3 cleavage as it moves 
distally down the axon would be impossible to determine, making this model 
extremely difficult to test with the tools currently available. 
 
Model 2: Cytochrome c is the triggering factor 
Cytochrome c, a central component in the mitochondrial apoptotic 
program, is a second possible candidate for the anterograde pro-degenerative 
signal. Waves of cytochrome c have been observed to propagate across other 
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cell types to activate the apoptotic program (Garcia-Perez et al., 2012; Lartigue et 
al., 2008), raising the possibility that as in the Caspase-3 model proposed above, 
a cytochrome c wave – one unable to induce cellular death – may be flowing out 
into the axons and nucleating the apoptosome. This model similarly requires the 
existence of a Puma-redundant factor and would predict that cytochrome c 
concentration in axons would increase after TD, which could be observed by 
Western blot of isolated axons or through immunofluorescence using a fine time 
course. Employing the mEOS strategy detailed above (tagging cytochrome c in 
this case) would also enable live imagining of cytochrome c movement in axons 
subject to TD. 
Model 3: An additional Bax activator is the triggering factor 
Finally, there is a distinct possibility that the anterograde signal is a Bax 
activating factor distinct from Puma, but dependent, at least in part, on it’s 
upregulation. In this model, the TD-induced Puma increase releases this factor 
from Bcl-xL and Bcl-w inhibition. It is possible that this protein is basally 
expressed or newly synthesized in response to TD, with its activity being partially 
JNK dependent in either scenario (Figure 4.5A, B). This model would posit 
several key characteristics that potential candidates should possess: (1) identity 
as a Bax activator; (2) the ability to bind to and be inhibited by Bcl-xL and/or Bcl-
w; (3) observable movement from the cell body to the axon in response to TD; 
and 4) a protective phenotype when genetically deleted. 
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Future studies could potentially identify this factor utilizing a candidate 
knockdown approach on top of a Puma knockout, which should, in theory, 
produce a Bax-like protective phenotype. The classical apoptotic regulator p53 is 
a particularly promising candidate, as we have shown it delays axon 
degeneration after TD by a mechanism independent of transcriptional activation 
of Puma (Figure 4.6). Furthermore, it can act as a direct Bax activator in a 
manner inhibited by binding Bcl-xL (Chipuk et al., 2004; Xu et al., 2006). This 
inhibitory binding of p53 to Bcl-xL is specifically disrupted by Puma with other 
pro-apoptotic Bcl-2 family members being much less effective (Chipuk et al., 
2005; Follis et al., 2013). Intriguingly, loss of p53 does not seem to affect 
Caspase-3 activation in cell bodies of explants subject to TD, but it does have a 
noticeable effect on axonal Caspase-3 activation (Figure 4.6C,D). It remains 
possible that p53 could still be influencing axon degeneration by transcriptional 
regulation of other targets. RNAseq experiments could potentially address this 
possibility. Additionally, if p53 protein moves out to the axon following TD, it 
would argue for a more direct role. 
Bid represents another compelling target for an anterograde signal within 
this model. First, it is the only pro-apoptotic Bcl-2 family member that can be 
observed in axons (Figure 3.2B). Secondly, cleavage of Bid to form the more 
apoptotically active isoform tBid is seen in both cell bodies and axons after TD 
(Fiure 3.2C,D). Bid cleavage can be mediated by Caspase-3 in a non-canonical 
process (Gross et al., 1999), so a mechanism can be envisioned whereby Puma 
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triggers sub-apoptotic somatic Caspase-3 activity, resulting in the formation of 
tBid that then flows out to the axon. The fact that Bid knockouts do not have a 
protective phenotype in whole explant culture seems to argue against its role as 
a triggering factor, but it remains possible that Bid deletion could have a 
phenotype in Campenot chambers where a program more specific to axon 
degeneration, rather than whole cell apoptosis, occurs. Furthermore, a Bid;Puma 
double knockout may have a more Bax-like phenotype than Puma  knockout 
alone, which would also lend credence to this possibility. 
Why is axon degeneration controlled by the cell body? 
Beyond defining the molecular steps leading from distal trophic deprivation 
to axon degeneration, our findings highlight the pivotal, active role of the cell 
body, which functions as a locus of control in axon degeneration in response to 
distal trophic factor deprivation. At a cellular/biochemical level, this central role of 
the cell body seems remarkable. Indeed, we find that distal trophic deprivation 
deactivates pro-survival Akt and activates pro-degenerative DLK signaling locally 
within axons (Figure 2.10) and the axons contain a fully functional apoptotic 
machinery (Figure 2.4). However, the upstream Akt/DLK signals are incapable of 
biochemically connecting to and activating the axonal caspase cascade directly 
within the axon, instead requiring retrograde activation of the somatic pro-
degenerative program, with Puma as an unexpected somatically-restricted gating 
factor. These findings highlight a remarkable biochemical compartmentalization 
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of the upstream activator and downstream effector pathways for control of 
degeneration within the axon.  
 Why would such a mechanism exist in the neuron? At a functional level, 
this compartmentalization and stringent control of distal axon degeneration by 
retrograde activation of a somatic cell death program may provide an essential 
buffer, ensuring that transient local changes in trophic support do not trigger 
irreversible local degeneration events, and instead allowing the cell body to 
integrate pro-degenerative and pro-survival signals to execute axon degeneration 
in a global and a coordinated fashion. Indeed, as can be observed in the pruning 
of mammalian layer V cortical neurons, a transcriptional program is required to 
mediate branch specific pruning in vivo (Luo and O’Leary, 2005; Weimann et al., 
1999). The necessity of this program is inherent in the fact that the cortical region 
that the neuronal cell body is located in determines which branch will be pruned, 
with neurons in the visual cortex pruning a different branch than those in the 
motor cortex (Luo and O’Leary, 2005; Vanderhaeghen and Cheng, 2010). This 
indicates that during development the axon’s environment is not inherently 
degenerative, otherwise projections from both motor and visual cortical neurons 
in the same area would both degenerate. In this respect, having the cell body as 
the central arbiter ensures removal of the proper branch based on integration of 
all available signals.  
 Within systems where there is evidence of branch specific pruning by an 
apoptotic mechanism, such as that seen in the Superior Colliculus, how exactly a 
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specific branch is targeted for degeneration without initiating Caspase activation 
in all branches remains an open question. An intriguing option would be a 
mechanism whereby the cell body, after integrating pro-degenerative cues, 
releases an anterograde pro-apoptotic signal that is repressed in all branches 
except those destined to degenerate. A recent study demonstrated that this could 
potentially be accomplished by altering levels of anti-apoptotic proteins, such as 
XIAP, in response to local axonal signals (Cusack et al., 2013). In addressing 
these questions, future studies will not only delineate the mechanisms of 
developmental axon pruning, but more broadly elucidate how cells can achieve 
effective biochemical compartmentalization. 
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Chapter 6: Materials and Methods 
 Mice   
Animals were bred and used according to IACUC protocols at The Rockefeller 
University. Embryos were harvested from pregnant dams at stage E12.5. Wild-
type cultures were generated from CD1 mice. For mutant strains, comparisons 
between wild-type and mutant embryos derive from the same pregnant female. 
The following knockout strains were used for this study: 
Table 6.1 Knockout mouse strains used in this study 
Null Allele Reference 
Bad (Ranger et al., 2003) 
Bcl-w (Ross et al., 1998) 
Bid (Yin et al., 1999) 
Bim (Bouillet et al., 1999) 
Caspase-3 (Kuida et al., 1996) 
Caspase-9 (Simon et al., 2012) 
Hrk KO (Coultas et al., 2007) 
Puma (Villunger et al., 2003) 
Bid;Bim and Puma;Bcl-w double knockout strains were generated by 
intercrossing doubly heterozygous mice. 
The following conditional knockout mice were used for this study: 
Table 6.2 Conditional knockout mouse strains used in this study 
Conditional Allele Reference 
Apaf1 unpublished, generated by Dr. 
Zhigang He, deposited at Jackson 
Laboratory 
Bcl-2 (Thorp et al., 2009) 
Bcl-Xl (Rucker et al., 2000) 
c-Jun (Behrens et al., 2002) 
DLK (Miller et al., 2009) 
Mcl-1 (Vikstrom et al., 2010) 
PTEN (Groszer et al., 2001) 
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As indicated within the text, conditional knockout strains were either crossed to a 
Nestin-Cre driver (Tronche et al., 1999) or maintained in isolation and 
subsequent cultures were infected with lentiviral Cre. The following transgenic 
and knock-in strains were used: 
Table 6.3 Transgenic mouse strains used in this study 
Allele Reference 
Cytoplasmic-NMNAT1 transgenic (Sasaki et al., 2009) 
TrkA F592A knock-in (Chen et al., 2005b) 
Cell culture 
Sensory neuron cultures were harvested from E12.5 embryos and grown in 
Neurobasal media containing 2% (v/v) B27 (Life Technologies), 0.45% (v/v) 
Glucose, 2 mM glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and 
supplemented with 50ng/mL NGF (Promega). Unless otherwise indicated, all 
cultures were grown on plastic plates coated with poly-D-lysine (PDL; 100 μg/ml) 
and mouse natural laminin (10μg/ml, Life Technologies). Cells were treated with 
mitotic inhibitor (5μM 5-fluorouracil and 5 μM uridine) the morning after plating. In 
cases where protein was harvested, sensory neurons were dissociated (0.05% 
Trypsin-EDTA) and re-suspended in culture media at 2x10^4 cells/μl. Cells were 
spotted (1μl) at the center of PDL-Laminin-coated 24 well plates that were air-
dried. Culture media was added following a 12-15min period in a humidified 
incubator to allow the cells to settle. Campenot chambers were generated as 
previously described (Nikolaev et al., 2009). Briefly, sensory neurons from E12.5 
embryos were dissociated and resuspended at a concentration of 2.5x10^6 
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cells/mL in Neurobasal/B27 media containing 0.35% methylcellulose (m/v). The 
axonal compartment of the Campenot chambers was filled with 500μL 
methylcellulose-containing media. A grease barrier was established at the bottom 
on the center compartment and 60μL of cells were loaded into the center 
compartment and allowed to settle overnight before 2.5 mL of media was added 
to the outer dish the following morning. The following day, mitotic inhibitor was 
added to the outer dish only and half media changes were performed every 2 
days without adding fresh mitotic inhibitor. Local degeneration assays were 
performed by rinsing the outer compartment of the chamber with Neurobasal 
media and replacing it with NB/B27 media containing NGF function-blocking 
antibody (50μg/mL).  
 
Measurement of axonal DEVDase activity  
Sensory neurons were cultured both for 2 days as DRG explants in 48 well plates 
or for 7 days as dissociated and re-aggregated spots (2x10^4 cells / spot) in 24 
well plates. Following treatment, the cell body region was removed with a manual 
punch-out for explants as previously described (Yang et al., 2013) or using a 
small scalpel for re- aggregated spots. Immediately after removal of the cell 
bodies, half of the media was removed and replaced with an equal volume of 
Caspase-Glo 3/7 reagent (Promega). Following a one-hour lysis at room 
temperature, the contents of each well was transferred to an opaque 96-well 
plate and luminescence was determined using a plate reader. For axon specific 
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measurements in neurons expressing cytoplasmic NMNAT1, axons were 
severed then subjected to TD, followed by lysis.  
 
Lentiviral production  
Lentiviral constructs and the associated packaging plasmids psPAX2 and 
pMD2.G were precipitated into 293FT using calcium phosphate. After 16 hours 
the media was switched to serum free viral production media: Ultraculture 
(Lonza) supplemented with 1% (v/v) Penn-Strep/L-glututamine, 1% (v/v) 100mM 
Sodium Pyruvate, 1% (v/v) 7.5% sodium bicarbonate, and 5 mM sodium 
butyrate. 293FT supernatants were harvested at the 46-hour time point, 
neutralized with 1M Tris-HCl, pH 7.5 to 50mM final concentration, and filtered 
through 0.45 μm polyethersulfone syringe filters. Lentiviral titer was determined 
using an ELISA-based quantification of p24 viral coat protein according to the 
manufacturer’s instruction (Clontech). Upon determining titer the virus was 
concentrated using Lenti-X concentrator (Clontech) and re-suspended in 
Neurobasal/B27 DRG media containing 50ng/mL NGF. Lentivirus was added to 
DRG cultures 1-2 days after plating at a multiplicity of infection (MOI) of 10. 
Lentiviral shRNA constructs in the pLKO.1 backbone were chosen from the 
Broad/TRC collection. For each gene of interest, 4-5 shRNA constructs were 
tested for efficient target knockdown by western blot. The following shRNA 
clones were selected for use: Bcl-xL (TRCN0000010905), Foxo3a 
(TRCN0000071614). Lentiviral shRNAs were produced as above without further 
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concentration. shRNA viruses were added at 2 days post-plating at 5-10 MOI. In 
all cases where lentivirus is used, cultures were harvested 7 days post-infection. 
Lentiviral GFP was generated using pLenti-CMV-GFP (Addgene #17445). cDNAs 
encoding Cre-IRES-GFP, cytoplasmic Nmnat1-(R125A/R127A), and myrAkt1 
were cloned in place of GFP using standard techniques.  
 
Protein harvest and Western blotting  
Axons and cell bodies were independently harvested from sensory neurons 
cultured as re-aggregated spots using either a biopsy punch needle or scalpel 
(Fine Science Tools) as previously described (Yang et al., 2013). To collect 
protein, cultures were first rinsed with Hank’s balanced salt solution followed by 
direct solubilization of axons and cell bodies in an SDS/Urea-based lysis buffer 
containing: 50 mM Tris-HCl (pH 6.8), 8M Urea, 10 % (w/v) SDS, 10mM sodium 
EDTA, 50 mM DTT, supplemented with Brilliant Blue G. Axon or cell body 
material from 5-10 spots were pooled for each condition. Proteins were resolved 
on 4-15% Tris-HCl gradient gels (Bio-Rad) and blotted using standard 
techniques. Primary antibodies used at 1:500 except Tuj1, which was used at 
1:2000. HRP conjugated secondary antibodies (Jackson ImmunoResearch) were 
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Immunohistochemistry  
Cultures were fixed in 4% Paraformaldehyde containing 10% sucrose for 20 
minutes at room temperature and either stored in PBS or immediately blocked for 
at least one hour at room temperature in 3-6% donkey serum in PBS containing 
0.1% Triton-X- 100 (PBS-X). Slides were incubated in primary antibody overnight 
in 3% donkey serum in PBS-X at room temperature in a humidified chamber. All 
primary antibodies were used at a dilution of 1:500 except Tuj1, which was used 
at 1:1000. Secondary antibodies coupled to Alexa-based dyes (Life 
Technologies) were added at 1:500 in 3% donkey serum in PBS-X. Slides were 
imaged on a Nikon Eclipse 90i wide-field fluorescence microscope.  
Bcl-xL Immunoprecipitation 
Cultures were lysed in 150 mM NaCl, 10 mM HEPES, pH 7.4, 0.3% CHAPS for 1 
hour on ice. Cellular debris was eliminated by spinning lysates at 20,000xg for 5 
minutes and cell were pre-cleared with protein A/G agarose beads (Santa Cruz). 
Protein was quantified and normalized by BCA (Pierce) and lysates were split 
into two equal volumes. For each condition Bcl-xL (54H6) was added at 1:250 
with equivalent concentration isotype control being added to the other tube. 
Immunoprecipitation carried out at 4°C overnight with rotation. The following 
morning 20μL of protein A/G beads were added to each sample, and then 
samples were rotated at 4°C for 1hr. Beads were spun down at 1000xg and 
washed 5x in CHAPS buffer before protein was dissociated in SDS/Urea-based 
lysis buffer at 37°C for 30 minutes. 
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Antibodies and inhibitors  
Table 6.4 Antibodies used in this study 
Antibody Source 
Bcl-w (31H4 mAb, #2724) Cell Signaling Technology 
Bcl-xL (54H6 mAb, #2764) Cell Signaling Technology 
Bcl-2 (D17C4 mAb, #3498) Cell Signaling Technology 
Puma (pAb, #7467) Cell Signaling Technology 
total Caspase-3 (8G10 mAb, 
#9665) 
Cell Signaling Technology 
cleaved Caspase-3 D175 (pAb, 
#9661) 
Cell Signaling Technology 
Phospho-Foxo3a S318/S321 (pAb, 
#9465) 
Cell Signaling Technology 
Phospho-Foxo3a S254 (pAb, 
#9466) 
Cell Signaling Technology 
total Foxo3a (75D8 mAb, #2497) Cell Signaling Technology 
Phospho-Akt T308 (C31E5E mAb, 
#2965) 
Cell Signaling Technology 
Phospho-Akt S473 (D9E mAb, 
#4060) 
Cell Signaling Technology 
total Akt (40D4 mAb, #2920) Cell Signaling Technology 
c-Jun (60A8 mAb, 9165) Cell Signaling Technology 
Foxo3a (#07-1719) Millipore 
Mcl-1 (600-401-394S) Rockland Immunochemicals 
TuJ1 Covance 
Fractin (AB3150) EMD-Millipore 
TrkA (AF1056) R&D 
 
Function-blocking NGF antibody was a kind gift from Genentech, Inc. The 
following inhibitors were used: GDC-0068, ABT-737 (Selleck Chemicals), JNK 
inhibitor VIII, 1NM-PP1 (EMD-Millipore), Lactacystin (Calbiochem).  
Mass Spectrometry  
To recover sufficient axonal material, DRGs were harvested at E12.5 to E13.5 
from 4 CD1 litters, dissociated as above, and 2.5 x 106 to 3 x 106 neurons were 
plated in 200 μl modified silicon dividers on a poly-D-lysine / laminin-coated 10cm 
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dishes. After three hours, Neurobasal / B27 media supplemented with 50ng/ml 
NGF was added and the silicone dividers were removed. At DIV 12, the plates 
were rinsed with Neurobasal/B27 without NGF and subjected to TD for 24hr 
using an anti-NGF function-blocking antibody. Axon and cell body samples were 
harvested by washing twice with Hank’s balanced salt solution and physical 
separation of axons and cell bodies using a razor as described (Yang et al., 
2013). Axon and cell body samples were homogenized in a triton- based buffer 
[100mM Bicine pH 8.0, 150mM NaCl, 270mM Sucrose, 1% Triton-X100], protein 
was quantified by BCA, and equal amounts were analyzed by 1-D SDS PAGE (4- 
20% gradient TGX gels Bio-Rad). Proteins were separated by SDS-PAGE and 
visualized using Colloidal Coomassie stain (Bio-Rad). Gel bands were excised 
between 17 and 36 kDa, based on molecular weight marker (MW), corresponding 
to the MW of Puma (confirmed by Western Blot). Protein bands were trypsinized 
as described previously (Shevchenko et al., 1996) and extracted peptides 
analyzed by LC-MS/MS (Ultimate 3000 nano-HPLC system coupled to a Q-
Exactive Plus mass spectrometer, Thermo Scientific). Peptides were separated 
on a C18 column (12cm/75 μm, 3 μm beads, Nikkyo Tecnologies) at 200 nl/min 
with a gradient increasing from 5% Buffer B/95% buffer A to 45% buffer B/55% 
Buffer A in 82 min (buffer A: 0.1% formic acid, buffer B: 0.1% formic acid in 
acetonitrile). LC-MS/MS experiments where performed as either data dependent 
or parallel reaction monitoring (PRM). For PRM experiments 15 peptides from 3 
proteins were targeted (Puma: DSPRPFPLGR, EIGAQLR, VEEEEWAR, 
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MoxADDLNAQYER, QEGSSPEPVEGLAR; 14-3-3 protein gamma: 
YLAEVATGEK, NCSETQYESK, NVTELNEPLSNEER, YLAEVATGEKR, 
TAFDDAIAELDTLNEDSYK; Capzb: NDLVEALKR, DYLLCDYNR, 
SGSGTMNLGGSLTR, LTSTVMLWLQTNK, LEVEANNAFDQYR). Data were 
recorded in profile mode. Precursor mass spectra were recorded between m/z 
300-1100 at 35,000 resolution. Tandem MS spectra were recorded at 17,500 
resolution with m/z 100 as lowest mass. Normalized collision energy was set at 
27, with AGC target and maximum injection time being 5e5, and was 100ms, 
respectively. Tandem MS matching: data were extracted using Proteome 
Discoverer 1.4 (Thermo Scientific) and searched against Uniprot complete 
Mouse proteome databases (January 2013) concatenated with common 
contaminants (Bunkenborg et al., 2010) using Mascot 2.4 (Matrix Science). N-
terminal glutamate to pyroglutamate conversion, oxidation of methionine, and 
protein N-terminal acetylation were allowed as variable modifications. Matched 
peptides were filtered using either Fixed Value peptide spectrum match (PSM) or 
Percolator (Spivak et al., 2009). PRM data were analyzed using Xcalibur Quan 
Browser 3.0.63 (Thermo Scientific). For Puma, intensities of the three (EIGAQLR) 
and four (MoxADDLNAQYER) most intense fragment ions with m/z greater than 
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Quantification of axon degeneration  
For explant cultures: For each explant at each time point, two non-overlapping 
fields were imaged using a 10x objective. The percentage of axons with 
fragmented morphology as assayed by TuJ1 immunostaining was calculated for 
each image and averaged across both images for each explant. Degeneration 
index was calculated by dividing each value within an individual experiment by 
the average degeneration of wild-type cultures at the terminal time point.  
For Campenot chambers: Chambers were imaged using a 10x objective and 
degeneration was calculated as the percentage of fragmented axons within an 
entire chamber.  
For dissociated and re-aggregated cultures: Two non-overlapping fields were 
imaged for each culture and degeneration was calculated as the average 
percentage of fragmented axons across both images. 
 
In vivo imaging 
Whole mount in vivo immunolabeling and imaging was performed according to 
previously established protocols within the lab (Renier et al., 2014). Briefly, 
embryos were fixed overnight at 4°C in 4% PFA and then for 1hr at room 
temperature the next day. Embryos were washed in PBS and treated with a 
methanol series (50%, 80%, 100%) for 1hr (2x each step). Following this, 
embryos were bleached in 5% H2O2 in 20% DMSO/methanol (1 vol 30% H2O2/1 
vol DMSO/4 vol methanol, ice cold) at 4°C overnight. Samples were then 
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rehydrated according to the published protocol and permeabilized in PBS/0.2% 
Triton X-100 for 1 hr twice before immunolabeling. Embryos were imaged on a 
light-sheet microscope (Ultramicroscope II, LaVision Biotec) equipped with a 
sCMOS camera (Andor Neo) and a 23/0.5 objective lens equipped with a 6 mm 
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Appendix 1: Effect of Puma deletion on neuronal 
apoptosis in vivo 
 This experiments listed in Chapters 3 and 4 clearly establish a central role 
for Puma in TD induced axon degeneration in vitro. We utilized iDISCO, a newly 
developed protocol that allows for immunolabeling and volume imaging of whole 
embryos (Renier et al., 2014), to image TrkA neurons within embryonic day 14.5 
(E14.5) Puma WT and KO embryos. Axon projections to the periphery appeared 
grossly similar in WT and KO embryos, in accordance with that seen in Bax and 
Caspase-3 mutants (Figure A1.1A, Nicolas Renier and Zhuhao Wu, unpublished 
data). This is possibly due to the limits of resolution associated with the imaging 
technique (ie. small nociceptive axon numbers within large bundles might not be 
captured fully). Notably however, genetic deletion of Puma led to partial 
preservation of an entire ganglion and its axonal projections (Figure A1.1A red 
arrow). This rostrally located ganglion, known as “Froriep’s ganglion”, is normally 
eliminated during development (Geffen and Goldstein, 1996). The fact that it 
remains in KO embryos is a striking demonstration of necessity of Puma for 
neuronal apoptosis in the developing embryo. This is further emphasized by the 
~40% reduction of Caspase-3 positive cells in DRGs at this stage of development 
in Puma mutants (Figure A2.1B,C). Future experiments could examine the effect 
of Puma across the entire range of development and quantify axonal Caspase-3 
in vivo.  
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Imaging individual degenerating DRG sensory axons during development is 
extremely challenging, but two approaches could be used in future experiments 
to overcome this limitation. First, in vivo pruning defects could be examined by 
crossing Puma knockouts to Plexin-A3/A4 double knockouts, which show 
defasciculation and misprojection of peripherally extending axons. These 
misprojected axons are largely eliminated during development in a Bax-
dependent fashion (Schoenmann et al., 2010). If deletion of Puma produces a 
similar phenotype, it would provide compelling evidence for an in vivo role of 
Puma in axon pruning. Secondly, developmental axon degeneration could be 
assessed in vivo using electron microscopy to determine the number of 
myelinated and unmyelinated axons in the sciatic nerve of knockout and wild-
type mice across the spectrum of development (E15, postnatal day 0 (P0), P7, 
P14 and at six weeks). Using this method, the Tessier-Lavigne lab showed that 
P14 Caspase-3 knockout mice showed an increase in unmyelinated fibers in the 
sciatic nerve compared to wild-type littermate controls (David Simon, 
unpublished). Examining Puma knockouts in this paradigm represents an 
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Figure A1.1 An in vivo role for Puma in neuronal apoptosis during 
development. (A) Puma is required for degeneration of Froriep’s ganglion. 
Whole mount labeling of E14.5 Puma WT and KO embryos for Trka using the 
iDISCO protocol. (B and C) Puma deletion reduces the number of Caspase-3 
positive cells in DRGs during development. Whole mount labeling of E14.5 Puma 
WT and KO embryos for cCasp3 using the iDISCO protocol. Max projections of 
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Appendix 2: Involvement of the ubiquitin proteasome 
system in axon degeneration 
 The Ubiquitin proteasome system (UPS) is the main mechanism for 
directed proteolysis in eukaryotic cells. Proteins are targeted for degeneration by 
attachment of ubiquitin chains to lysine residues through a mechanism involving 
substrate specific E3 ligases (Finley, 2009). This system also contains substrate 
specific deubiquitinating enzymes (DUbs), also called ubiquitin proteases, that 
can remove ubiquitin chains from substrates. In addition to proteolytic functions, 
ubiquitination also plays key roles in cell signaling (Chen and Sun, 2009), 
including playing a role in TrkA internalization that is necessary for endocytosis 
and signaling (Wooten and Geetha, 2006). 
 Recent studies have shown that ubiquitination of Caspase-8 plays a major 
role in initiating the extrinsic apoptotic pathway in human cell lines (Jin et al., 
2009) and factors that activate proteasome activity play a key role in the caspase 
activation necessary for spermatogenesis in Drosophila (Bader et al., 2011). The 
UPS also plays key regulatory roles in intrinsic apoptotic pathways, including 
regulation of anti-apoptotic Bcl-2 family members Bcl-xL, Bcl-2, and Mcl-1, as 
well as pro-apoptotic members including Bim and Bid (Neutzner et al., 2012; 
Vucic et al., 2011). Moreover, ubiquitination of Bax by the E3 ligase Parkin has 
an anti-apoptotic effect in neuronal cell lines (Johnson et al., 2012). Additionally, 
over expression of a specific DUb can reduce stereotyped pruning in Drosophila 
mushroom bodies and inhibition of the proteasome with the irreversible inhibitor 
	   125 
lactacystin protects mouse sympathetic axons from degeneration in vitro both in 
response to physical injury and in response to TD (Watts et al., 2003; Zhai et al., 
2003).  
 To gain a better mechanistic insight into the role of the UPS in axon 
degeneration we assayed Caspase-3 activation after TD in the presence of the 
proteasome inhibitor lactacystin. Proteasome inhibition delays axon degeneration 
after TD, confirming earlier studies, and it appears to act upstream of Caspase-3 
activation, as the immunoreactivity of cleaved Caspase-3 in axons was also 
noticeably reduced (Figure A2.1A). We reasoned that this effect could be a result 
of increasing concentration of Bcl-2 family members normally degraded by the 
UPS. While only producing a small increase in Bcl-xL and no noticeable increase 
in Bcl-w, levels of Mcl-1 were dramatically upregulated in axons of DRG cultures 
treated with the proteasome inhibitor lactacystin in the presence of NGF (Figure 
A2.1B). This was surprising in that Mcl-1 could only be observed at extremely low 
levels basally in DRGs untreated with lactacystin and Mcl-1 levels in cell bodies 
were not affected by NGF withdrawal (Figure A2.1B, 3.8A.B). This may indicate 
that the mechanism by which proteasome inhibition protects axons is by raising 
the threshold of activation of the mitochondrial apoptotic pathway through 
increased anti-apoptotic protein concentration. Further, it may indicate that Mcl-1 
is normally restricted to the cell body in healthy neurons by the activity of the 
proteasome, providing a mechanism whereby cell bodies are more resistant to 
apoptotic stressors than axons. Both of these possibilities warrant further study. 





Figure A2.1 The role of the proteasome in Caspase activation in axons 
after TD. (A) Proteasome inhibition delays activation of axonal Caspase-3 after 
TD. 2DIV DRG explant cultures were subject to 9hr TD or pretreated for 1hr with 
10μM lactacystin and subjected to 9hr TD in the presence of lactacystin as 
indicated. Caspase-3 activation was assayed by immunofluorescence. (B) 7DIV 
DRG explants were treated with 10μM lactacystin or DMSO for 15hr and highly 
enriched axonal preparations were collected. Levels of anti-apoptotic Bcl-2 family 
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Appendix 3: Rights and permissions 
Figure 1.1 
Reprinted from Trends in Cell Biology, 24, Neukomm, L.J., and Freeman, M.R. 
Diverse cellular and molecular modes of axon degeneration, 515–523, Copyright 
(2014), with permission from Elsevier. 
 
Figure 1.2A 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews 
Neuroscience, Chao, M.V. Neurotrophins and their receptors: A convergence 
point for many signalling pathways. 4, 299–309, copyright (2003) 
 
Figure 1.2B, 1.4A 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews 
Neuroscience, Zweifel, L.S., Kuruvilla, R., and Ginty, D.D. Functions and 
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